<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9737020</article-id><article-id pub-id-type="pmcid-ver">PMC9737020.1</article-id><article-id pub-id-type="pmcaid">9737020</article-id><article-id pub-id-type="pmcaiid">9737020</article-id><article-id pub-id-type="pmid">36499021</article-id><article-id pub-id-type="doi">10.3390/ijms232314694</article-id><article-id pub-id-type="publisher-id">ijms-23-14694</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A New Role of NAP1L1 in Megakaryocytes and Human Platelets</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2649-5710</contrib-id><name name-style="western"><surname>Freitag</surname><given-names initials="M">Martin</given-names></name><xref rid="af1-ijms-23-14694" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schwertz</surname><given-names initials="H">Hansj&#246;rg</given-names></name><xref rid="af2-ijms-23-14694" ref-type="aff">2</xref><xref rid="af3-ijms-23-14694" ref-type="aff">3</xref><xref rid="af4-ijms-23-14694" ref-type="aff">4</xref><xref rid="c1-ijms-23-14694" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Catani</surname><given-names initials="MV">Maria Valeria</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-23-14694"><label>1</label>Department of Cardiac Surgery, Heart Center Leipzig-University Hospital, 04289 Leipzig, Germany</aff><aff id="af2-ijms-23-14694"><label>2</label>Molecular Medicine Program, University of Utah, Salt Lake City, UT 84112, USA</aff><aff id="af3-ijms-23-14694"><label>3</label>Division of Occupational Medicine, University of Utah, Salt Lake City, UT 84112, USA</aff><aff id="af4-ijms-23-14694"><label>4</label>Occupational Medicine at Billings Clinic Bozeman, Bozeman, MT 59715, USA</aff><author-notes><corresp id="c1-ijms-23-14694"><label>*</label>Correspondence: <email>hansjorg.schwertz@u2m2.utah.edu</email> or <email>hschwertz@billingsclinic.org</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2022</year></pub-date><volume>23</volume><issue>23</issue><issue-id pub-id-type="pmc-issue-id">423445</issue-id><elocation-id>14694</elocation-id><history><date date-type="received"><day>12</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>11</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>11</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-03 20:25:30.820"><day>03</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-23-14694.pdf"/><abstract><p>Platelets (PLTs) are anucleate and considered incapable of nuclear functions. Contrastingly, nuclear proteins were detected in human PLTs. For most of these proteins, it is unclear if nuclear or alternatively assigned functions are performed, a question we wanted to address for <underline>n</underline>uclear <underline>a</underline>ssembly <underline>p</underline>rotein <underline>1</underline>
<underline>l</underline>ike <underline>1</underline> (NAP1L1). Using a wide array of molecular methods, including RNAseq, co-IP, overexpression and functional assays, we explored expression pattern and functionality of NAP1L1 in PLTs, and CD34<sup>+</sup>-derived megakaryocytes (MKs). NAP1L1 is expressed in PLTs and MKs. Co-IP experiments revealed that dihydrolipolylysine-residue acetyltransferase (DLAT encoded protein PDC-E2, ODP2) dynamically interacts with NAP1L1. PDC-E2 is part of the mitochondrial pyruvate-dehydrogenase (PDH) multi-enzyme complex, playing a crucial role in maintaining cellular respiration, and promoting ATP-synthesis via the respiratory chain. Since altered mitochondrial function is a hallmark of infectious syndromes, we analyzed PDH activity in PLTs from septic patients demonstrating increased activity, paralleling NAP1L1 expression levels. MKs PDH activity decreased following an LPS-challenge. Furthermore, overexpression of NAP1L1 significantly altered the ability of MKs to form proplatelet extensions, diminishing thrombopoiesis. These results indicate that NAP1L1 performs in other than nucleosome-assembly functions in PTLs and MKs, binding a key mitochondrial protein as a potential chaperone, and gatekeeper, influencing PDH activity and thrombopoiesis.</p></abstract><kwd-group><kwd>co-immunoprecipitation</kwd><kwd>DLAT</kwd><kwd>ODP2</kwd><kwd>PDC-E2</kwd><kwd>megakaryocytes</kwd><kwd>NAP1L1</kwd><kwd>overexpression</kwd><kwd>platelets</kwd><kwd>protein interactions</kwd><kwd>sepsis</kwd></kwd-group><funding-group><award-group><funding-source>Volkswagen Foundation</funding-source></award-group><award-group><funding-source>National Aeronautics and Space Administration</funding-source><award-id>80NSSC22K0255</award-id></award-group><award-group><funding-source>Molecular Medicine at the University of Greifswald</funding-source><award-id>MF_HJ-FVMM-FVCM-2014_06051</award-id></award-group><funding-statement>In the preparation of this manuscript H. Schwertz was supported by a Lichtenberg-Professorship from the Volkswagen Foundation, and the National Aeronautics and Space Administration (NASA, Space Biology 80NSSC22K0255). The material contained in this document is based upon work supported by a National Aeronautics and Space Administration (NASA) grant or cooperative agreement. Any opinions, findings, conclusions or recommendations expressed in this material are those of the author and do not necessarily reflect the views of NASA. M. Freitag was supported by a start-up grant by Molecular Medicine at the University of Greifswald (MF_HJ-FVMM-FVCM-2014_06051).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-23-14694"><title>1. Introduction</title><p>Megakaryocytes (MKs) are highly specialized precursor cells, residing in the bone marrow [<xref rid="B1-ijms-23-14694" ref-type="bibr">1</xref>] and lungs [<xref rid="B2-ijms-23-14694" ref-type="bibr">2</xref>], that produce and finally release platelets (PLTs) [<xref rid="B3-ijms-23-14694" ref-type="bibr">3</xref>,<xref rid="B4-ijms-23-14694" ref-type="bibr">4</xref>,<xref rid="B5-ijms-23-14694" ref-type="bibr">5</xref>]. The development and maturation of MKs and the subsequent production of PLTs by MKs are tightly regulated and depend on external cues [<xref rid="B6-ijms-23-14694" ref-type="bibr">6</xref>,<xref rid="B7-ijms-23-14694" ref-type="bibr">7</xref>,<xref rid="B8-ijms-23-14694" ref-type="bibr">8</xref>]. During the final stages of MK development, the cytoplasm is massively reorganized and long cytoplasmic extensions are formed, coined proplatelets [<xref rid="B9-ijms-23-14694" ref-type="bibr">9</xref>]. Two cytoskeletal systems provide the force leading to the shape changes associated with MK maturation and proplatelet formation: actin filaments and microtubules assembled from tubulin subunits [<xref rid="B10-ijms-23-14694" ref-type="bibr">10</xref>,<xref rid="B11-ijms-23-14694" ref-type="bibr">11</xref>]. More specifically, it was demonstrated that dynein-dependent microtubule sliding acts as the driving force for proplatelet elongation and PLT biogenesis [<xref rid="B11-ijms-23-14694" ref-type="bibr">11</xref>]. In this context, it is important to note that such processes are strictly dependent on sufficient availability of ATP as an energy source [<xref rid="B12-ijms-23-14694" ref-type="bibr">12</xref>].</p><p>Once released into the circulation, PLTs impose as small, and anucleate cells. In the past, PLTs have traditionally been considered simple &#8216;sacs of glue&#8217; with limited functionality beyond acute hemostasis due to the lack of a cell nucleus. However, in recent years, PLTs have been identified as dynamic effector cells bridging the inflammatory, immune, and hemostatic continuum [<xref rid="B6-ijms-23-14694" ref-type="bibr">6</xref>,<xref rid="B7-ijms-23-14694" ref-type="bibr">7</xref>,<xref rid="B8-ijms-23-14694" ref-type="bibr">8</xref>,<xref rid="B13-ijms-23-14694" ref-type="bibr">13</xref>,<xref rid="B14-ijms-23-14694" ref-type="bibr">14</xref>,<xref rid="B15-ijms-23-14694" ref-type="bibr">15</xref>,<xref rid="B16-ijms-23-14694" ref-type="bibr">16</xref>]. One mechanism explaining the multitude of functional responses is that MKs are equipped to sense external stimuli that trigger differential expression and packaging of mRNA and proteins into their progeny, causing distinct PLT functional alterations, especially in disease [<xref rid="B6-ijms-23-14694" ref-type="bibr">6</xref>,<xref rid="B7-ijms-23-14694" ref-type="bibr">7</xref>,<xref rid="B8-ijms-23-14694" ref-type="bibr">8</xref>,<xref rid="B17-ijms-23-14694" ref-type="bibr">17</xref>,<xref rid="B18-ijms-23-14694" ref-type="bibr">18</xref>,<xref rid="B19-ijms-23-14694" ref-type="bibr">19</xref>,<xref rid="B20-ijms-23-14694" ref-type="bibr">20</xref>,<xref rid="B21-ijms-23-14694" ref-type="bibr">21</xref>]. Hence, although PLTs are anucleate, we found that the PLTs&#8217; array of mRNAs is dynamic and can undergo active re-programming [<xref rid="B8-ijms-23-14694" ref-type="bibr">8</xref>,<xref rid="B17-ijms-23-14694" ref-type="bibr">17</xref>,<xref rid="B18-ijms-23-14694" ref-type="bibr">18</xref>,<xref rid="B19-ijms-23-14694" ref-type="bibr">19</xref>]. Furthermore, intricate processes regulate RNA processing, expression, and translational events [<xref rid="B22-ijms-23-14694" ref-type="bibr">22</xref>,<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>,<xref rid="B25-ijms-23-14694" ref-type="bibr">25</xref>,<xref rid="B26-ijms-23-14694" ref-type="bibr">26</xref>,<xref rid="B27-ijms-23-14694" ref-type="bibr">27</xref>,<xref rid="B28-ijms-23-14694" ref-type="bibr">28</xref>] in PLTs. In concert with maintaining nuclear RNA processing capabilities, numerous studies have shown that PLTs possess nuclear proteins, such as the peroxisome proliferator-activated receptor (PPAR)-c, and retinoid X receptor (RXR) [<xref rid="B29-ijms-23-14694" ref-type="bibr">29</xref>,<xref rid="B30-ijms-23-14694" ref-type="bibr">30</xref>], and retinoic acid receptor (RAR) [<xref rid="B28-ijms-23-14694" ref-type="bibr">28</xref>,<xref rid="B31-ijms-23-14694" ref-type="bibr">31</xref>].</p><p>Sepsis is a common, and often morbid, syndrome which is characterized by systemic inflammation and dysregulated host immune responses triggered by invading pathogens or toxins (i.e., Toll-like receptor [TLR] agonists like LPS), frequently intensified by injurious agonists generated by the infected organism. The MK-PLT axis plays a major role in orchestrating sepsis-related thromboinflammatory and immunothrombotic events [<xref rid="B7-ijms-23-14694" ref-type="bibr">7</xref>,<xref rid="B32-ijms-23-14694" ref-type="bibr">32</xref>,<xref rid="B33-ijms-23-14694" ref-type="bibr">33</xref>,<xref rid="B34-ijms-23-14694" ref-type="bibr">34</xref>,<xref rid="B35-ijms-23-14694" ref-type="bibr">35</xref>]. MKs were demonstrated to synergistically react to TLR 2/4 agonists in combination with thrombopoietin (TPO) signaling by increasing their proliferation, and thrombopoiesis [<xref rid="B36-ijms-23-14694" ref-type="bibr">36</xref>]. However, this effect could only be observed in immature CD34+ cells, while MKs in the past 7 days of culture demonstrated slightly decreasing numbers when treated with LPS. Finally, PLT aggregation and the formation of heterotypic PLT-leukocyte aggregates in septic patients is associated with increased morbidity and mortality [<xref rid="B37-ijms-23-14694" ref-type="bibr">37</xref>,<xref rid="B38-ijms-23-14694" ref-type="bibr">38</xref>,<xref rid="B39-ijms-23-14694" ref-type="bibr">39</xref>]. Nevertheless, the direct impact of PLTs in the pathobiology of sepsis remains incompletely understood. Furthermore, several cell biology aspects, and mechanistic insight into PLT and MK functions during septic events are still obscure.</p><p>The purification and functional characterization of a 53 kDa protein facilitating nucleosome assembly in mammalian cells was first described in 1984 [<xref rid="B40-ijms-23-14694" ref-type="bibr">40</xref>]. The NAP-family, including nucleosome assembly protein 1 like 1 (NAP1L1), is a group of proteins with chaperone function, capable of binding histones and coordinating their assemblance into nucleosomal particles [<xref rid="B41-ijms-23-14694" ref-type="bibr">41</xref>]. Several additional binding partners for NAP-family members were identified, including transcription factors, proteins regulating nuclear import (karyopherins), and factors involved in cell cycle regulation (reviewed in [<xref rid="B41-ijms-23-14694" ref-type="bibr">41</xref>]). Specifically, NAP1L1 was described to promote proliferation of pluripotent stem cells [<xref rid="B42-ijms-23-14694" ref-type="bibr">42</xref>] through cell cycle interference. Furthermore, NAP1L1, in concert with NAP1L4, can act as a histone chaperone [<xref rid="B43-ijms-23-14694" ref-type="bibr">43</xref>], and serving as a co-factor for ubiquitination client selection [<xref rid="B44-ijms-23-14694" ref-type="bibr">44</xref>]. Furthermore, numerous studies describe NAP1L1 as a prognostic marker in select cancer entities (i.e., colon cancer [<xref rid="B45-ijms-23-14694" ref-type="bibr">45</xref>], hepatocellular carcinoma [<xref rid="B46-ijms-23-14694" ref-type="bibr">46</xref>], ovarian cancer [<xref rid="B47-ijms-23-14694" ref-type="bibr">47</xref>], and lung cancer [<xref rid="B48-ijms-23-14694" ref-type="bibr">48</xref>]), and its involvement in a number of signaling pathways, which were demonstrated to result in tumor progression.</p><p>NAP1L1 mRNA expression in human PLTs was previously described [<xref rid="B49-ijms-23-14694" ref-type="bibr">49</xref>]; however, no function was assigned to this versatile nuclear protein in such anucleate cells, or its progenitors, MKs. Here, we demonstrate that MKs and human PLTs endogenously express differential NAP1L1 mRNA variants and protein isoforms. We identified PDC-E2, a subunit of the mitochondrial pyruvate dehydrogenase (PDH complex), as a protein interaction partner. In PLTs, septic conditions induced increased expression of NAP1L1 protein, and PDH complex activity. In contrast, exogenous overexpression of NAP1L1 in MKs resulted in reduced proplatelet formation, and decreased PDH complex activity when treated with LPS, simulating a septic environment. Our findings suggest a previously unidentified NAP1L1 interaction partner in human PLTs and MKs. Furthermore, this newly described protein&#8211;protein interaction seems to influence PDH complex activity, with subsequent functional disturbances of these specialized cells.</p></sec><sec sec-type="results" id="sec2-ijms-23-14694"><title>2. Results</title><sec id="sec2dot1-ijms-23-14694"><title>2.1. CD34<sup>+</sup>-Derived MKs and Freshly Isolated Human PLTs Express NAP1L1</title><p>We initially sought to determine RNA expression patterns of <italic toggle="yes">NAP1L1</italic> in CD34<sup>+</sup> hematopoietic progenitor cell-derived MKs and freshly isolated human PLTs. Next generation RNA-sequencing (RNA-seq) revealed that MKs and human PLTs express messenger RNA (mRNA) for <italic toggle="yes">NAP1L1</italic> (<xref rid="ijms-23-14694-f001" ref-type="fig">Figure 1</xref>A,B). Consistent with its expression demonstrated via RNA-seq, <italic toggle="yes">NAP1L1</italic> mRNA was also detected in MKs using PCR techniques (<xref rid="ijms-23-14694-f001" ref-type="fig">Figure 1</xref>C). <italic toggle="yes">NAP1L1</italic> was consistently expressed over the entire time course of MK culture and differentiation. Furthermore, <italic toggle="yes">NAP1L1</italic> was readily detectable in RNA samples isolated from human PLTs (<xref rid="ijms-23-14694-f001" ref-type="fig">Figure 1</xref>D). Of note, all PLT samples used for these studies were DNase treated to exclude any DNA contaminants from nucleated cells.</p><p>Since multiple alternative transcripts are described to exist for <italic toggle="yes">NAP1L1</italic>, we next performed PCR experiments using a primer pair spanning from exon 1 to exon 7, enabling us to detect a potential alternative <italic toggle="yes">NAP1L1</italic> transcript variant 5, which is devoid of exons 3 and 4 (<xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>A). MKs as well as PLT samples demonstrated the presence of PCR products indicative of <italic toggle="yes">NAP1L1</italic> transcript variant 1 (<xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>B,C), PCR product band indicated at ~600 bp) and transcript variant 5 (<xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>B,C, PCR product band indicated at ~400 bp). These findings were verified by Sanger sequencing for excised PCR products, demonstrating full length transcript as well as a transcript devoid of exon 3 and 4 (data not shown). In addition, we were able to detect <italic toggle="yes">NAP1L1</italic> transcript variants at all stages of MK differentiation (<xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>B). Furthermore, allowing the incubation of PLTs overnight (<xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>C), or the placement of PLTs on immobilized fibrinogen and stimulating the cells using thrombin (<xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S1</xref>) did not alter the expression pattern of alternative transcripts; therefore, no loading control was included.</p><p>Consistent with our findings by PCR and Sanger sequencing (<xref rid="ijms-23-14694-f001" ref-type="fig">Figure 1</xref> and <xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>, and data not shown), we found that NAP1L1 protein is endogenously and robustly expressed in situ in the cytoplasm and proplatelet extensions of MKs (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>A). It is interesting to note that NAP1L1 protein localization in MKs is less pronounced in cell nuclei; however, it demonstrates some peri-nuclear enhancement. Furthermore, cells undergoing anaphase showed reduced NAP1L1 association with condensed chromosomes (<xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S2</xref>). While nucleosome assembly proteins were initially identified as being histone chaperones and chromatin-assembly factors, additional functions were assigned including tissue-specific transcription regulation, apoptosis, histone shuttling, cell-cycle regulation, and additional chaperone functions beyond histone binding [<xref rid="B41-ijms-23-14694" ref-type="bibr">41</xref>]. Our microscopic findings in MKs could potentially point towards such extra nuclear functions.</p><p>In unstimulated human PLTs, NAP1L1 protein concentrated and accumulated peri-granular (when compared with WGA co-staining) in a fine vesicular pattern (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>B).</p><p>Immunoblotting also confirmed our microscopic findings of NAP1L1 protein being present in MKs (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>C). Surprisingly, Western blotting revealed three major protein bands at 60, 53 and 37 kDa, while the predicted size for NAP1L1 protein (expected isoform 1) is 43&#8211;53 kDa. Therefore, we sought to examine the specificity of the used anti-NAP1L1 antibody. A peptide competition assay (quench experiment) using the immunogenic peptide (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>D, right) showed that all three detected protein bands specifically represent NAP1L1 isoforms or potentially post-translational modified NAP1L1 in human PLT samples (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>D, left).</p></sec><sec id="sec2dot2-ijms-23-14694"><title>2.2. NAP1L1 Directly Interacts with the Dihydrolipopolylysine-Residue Acetyltransferase Component of Pyruvate Dehydrogenase Complex (PDC-E2, ODP2)</title><p>Because of its multitude of functions described in the literature, and its widely unknown roles in MK and PLT cell biology, we next wanted to identify NAP1L1 protein binding partners in human PLTs. To identify such interaction partners, we used carefully controlled co-IP experiments followed by mass spectroscopy (MS) analyses of a selected band. We identified a highly specific protein, which was only present in the specific anti-NAP1L1 pull-down (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>A, second lane from left); however, was absent in the isotype-specific IgG control (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>A, third lane from left). Furthermore, we excluded non-specific binding to the protein G magnetic beads by including a control condition using those beads only (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>A, right lane).</p><p>Besides contaminating human cytokeratin, which was most likely introduced during protein processing, we found the highest total spectrum count being present for ODP2_HUMAN (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>B), the human mitochondrial dihydrolipoyllysine-residue acetyltransferase component (PDC-E2). The highly specific nature of this identified NAP1L1 binding partner was further underscored by its significantly increased normalized spectrum count for peptide sequences, when compared to samples co-IPed using IgG (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>C). Consistent with its expression pattern at the peptide level, immunoblotting demonstrated robust and specifically detectable NAP1L1&#8212;PDC-E2 protein interaction in human PLTs (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>D) using Western blot approaches.</p><p>PDC-E2&#8212;human mitochondrial dihydrolipoyllysine-residue acetyltransferase is the E2 component of the multi-enzyme pyruvate dehydrogenase complex (PDC). In nucleated cells, DLAT, the gene encoding PDC-E2, is part of the nuclear DNA, and upon translation, the protein needs to be transported to the inner mitochondria membrane. Here, the enzyme transfers acetyl groups to coenzyme A. In addition, PDC can also be present in the nucleus catalyzing histone acetylation [<xref rid="B50-ijms-23-14694" ref-type="bibr">50</xref>,<xref rid="B51-ijms-23-14694" ref-type="bibr">51</xref>]. In turn, PDC-E2 is also the key antigen in primary biliary cholangitis, a chronic liver disease with autoimmune component targeting intrahepatic bile duct lining cells [<xref rid="B52-ijms-23-14694" ref-type="bibr">52</xref>,<xref rid="B53-ijms-23-14694" ref-type="bibr">53</xref>].</p></sec><sec id="sec2dot3-ijms-23-14694"><title>2.3. NAP1L1 and PDC-E2 Show Dynamic Expression Changes When PLTs Are Exposed to Septic Conditions</title><p>NAP1L1 was previously assigned chaperone and transport functions, involving histone complexes [<xref rid="B54-ijms-23-14694" ref-type="bibr">54</xref>,<xref rid="B55-ijms-23-14694" ref-type="bibr">55</xref>], diacylglycerol kinase &#950; [<xref rid="B56-ijms-23-14694" ref-type="bibr">56</xref>], mtHsp70 [<xref rid="B57-ijms-23-14694" ref-type="bibr">57</xref>]. Here, we add an additional interaction partner, PDC-E2, to the evolving functional repertoire of NAP1L1. With PDC-E2 being an integral part of the mitochondrial pyruvate dehydrogenase complex, we started exploring functional consequences of the NAP1L1&#8211;PDC-E2 interaction. Several studies demonstrated that the mitochondrial pyruvate dehydrogenase complex gets dysregulated due to septic host environment [<xref rid="B58-ijms-23-14694" ref-type="bibr">58</xref>,<xref rid="B59-ijms-23-14694" ref-type="bibr">59</xref>]. Although anucleate, emerging data demonstrates that the human PLT transcriptome is not static. Rather, the PLT transcriptome is dynamic and markedly altered during systemic inflammatory diseases [<xref rid="B6-ijms-23-14694" ref-type="bibr">6</xref>,<xref rid="B7-ijms-23-14694" ref-type="bibr">7</xref>,<xref rid="B22-ijms-23-14694" ref-type="bibr">22</xref>,<xref rid="B26-ijms-23-14694" ref-type="bibr">26</xref>]. Therefore, we sought to examine NAP1L1 and PDC-E2 protein expression levels in human PLTs isolated from septic patients.</p><p>To determine whether transcripts coding for NAP1L1 were altered in PLTs during sepsis, we used RNA-seq on highly purified PLTs from septic patients and matched healthy donors. This study was performed as a sub-analysis of a dataset previously published by our group [<xref rid="B8-ijms-23-14694" ref-type="bibr">8</xref>]. <xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref>A demonstrates the significant increase in mRNA coding for <italic toggle="yes">NAP1L1</italic> in PLTs isolated from septic patients.</p><p>Having detected significantly increased <italic toggle="yes">NAP1L1</italic> transcript levels in PLTs from septic patients, we hypothesized that NAP1L1 protein expression would similarly be altered during sepsis. We initially used immunofluorescence staining (ICC) to examine NAP1L1 protein expression and localization in PLTs from septic patients and matched healthy control donors. NAP1L1 staining was localized peri-granular (when compared with WGA co-staining) in a fine vesicular pattern (<xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref>B). In septic PLTs, using automated image analysis, we detected an increased mean fluorescent intensity for NAP1L1 (<xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref>C), which translated into a significant fold-increase of staining intensity (data not shown).</p><p>To further test the above hypothesis, we used Western blot analysis to examine total PLT NAP1L1 protein expression. <xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref>D,E demonstrate significantly increased NAP1L1 protein expression in PLTs from septic patients.</p><p>In contrast to the increased NAP1L1 expression, Western blot analysis for PDC-E2 showed significantly decreased total protein expression in PLTs isolated from septic patients when compared to healthy controls (<xref rid="ijms-23-14694-f006" ref-type="fig">Figure 6</xref>A,B).</p></sec><sec id="sec2dot4-ijms-23-14694"><title>2.4. Pyruvate Dehydrogenase Complex Activity Is Increased in PLTs during Sepsis</title><p>The immunometabolism during sepsis is characterized by a switch from a high-energy infection resistance mode to a low-energy conservation tolerance mode within 4&#8211;8 h after sepsis dissemination [<xref rid="B58-ijms-23-14694" ref-type="bibr">58</xref>]. The pyruvate dehydrogenase complex acts as an energy homeostat, and its deactivation creates an energy supply chain shortage during sepsis. Here, pyruvate dehydrogenase (PDH) complex activity was significantly increased in PLTs isolated from septic patients when compared to healthy donor PLTs (<xref rid="ijms-23-14694-f006" ref-type="fig">Figure 6</xref>C), which could indicate an early stage in the septic continuum.</p></sec><sec id="sec2dot5-ijms-23-14694"><title>2.5. NAP1L1 Overexpression in MKs Induced Reduced Proplatelet Formation (PPF)</title><p>To further establish potential functional consequences of the newly described NAP1L1&#8211;PDC-E2 protein interaction, we utilized an established CD34<sup>+</sup>-derived human MK cell culture model [<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>,<xref rid="B31-ijms-23-14694" ref-type="bibr">31</xref>,<xref rid="B60-ijms-23-14694" ref-type="bibr">60</xref>].</p><p>MKs are PLT precursor cells, contain many of the same proteins and pathways as PLTs, and are often used as a relevant model system to study PLT responses [<xref rid="B8-ijms-23-14694" ref-type="bibr">8</xref>,<xref rid="B60-ijms-23-14694" ref-type="bibr">60</xref>,<xref rid="B61-ijms-23-14694" ref-type="bibr">61</xref>]. While PLTs are only extremely difficult or not at all accessible to modifications of their transcriptome, MKs have been genetically modified using several different techniques [<xref rid="B62-ijms-23-14694" ref-type="bibr">62</xref>,<xref rid="B63-ijms-23-14694" ref-type="bibr">63</xref>]. Here, we used &#8220;liposome-based transfection&#8221; utilizing the transfer of in vitro transcribed, capped, and poly(A) tailed <italic toggle="yes">NAP1L1</italic> mRNA into MKs (<xref rid="ijms-23-14694-f007" ref-type="fig">Figure 7</xref>A), to induce transient overexpression of NAP1L1. <xref rid="ijms-23-14694-f007" ref-type="fig">Figure 7</xref>B demonstrates the successful overexpression of NAP1L1 protein in MKs. In contrast to PLTs isolated from septic patients, the exposure of human MKs to an agonist commonly generated during sepsis (lipopolysaccharide, LPS) did result in a slight decrease of the endogenous NAP1L1 protein level, independent of the transfection. In addition, treatment of transfected cells with LPS did also not lead to NAP1L1 protein levels above the non-LPS but transfected condition. We next analyzed proplatelet formation (PPF), an energy intensive hallmark functional determinate of MKs in NAP1L1 transfected cell cultures. We were able to show that NAP1L1 protein overexpression in non-treated cells, and even more pronounced in with LPS-treated cells, significantly decreased PPF (<xref rid="ijms-23-14694-f007" ref-type="fig">Figure 7</xref>C,D). Additional co-IP experiments using MKs demonstrated increased NAP1L1&#8211;PDC-E2 interaction when cells were exposed to LPS (<xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S3A</xref>). Furthermore, consistent with the PPF data indicating decreased functional capacity of MKs under septic conditions, LPS treatment decreased the pyruvate dehydrogenase complex activity in our culture model (<xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S3B</xref>).</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-23-14694"><title>3. Discussion</title><p>The MK-PLT axis is increasingly recognized as being more intricate and sophisticated in cellular responsibilities and abilities than historically expected. MKs are not only producing PLTs in the bone marrow through thrombopoiesis but are also intimately involved in setting up the PLT immune potential. MKs invest PLTs with the molecular composition to take center stage as responders and immune sentinels in the initiation and propagation of coordinated host immune responses [<xref rid="B64-ijms-23-14694" ref-type="bibr">64</xref>]. Furthermore, while PLTs are anucleate, it has been demonstrated that they contain a complex transcriptome [<xref rid="B20-ijms-23-14694" ref-type="bibr">20</xref>,<xref rid="B49-ijms-23-14694" ref-type="bibr">49</xref>] and regulatory pathways, including cytoplasmic splicing, controlling important biologic tasks [<xref rid="B22-ijms-23-14694" ref-type="bibr">22</xref>,<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>,<xref rid="B26-ijms-23-14694" ref-type="bibr">26</xref>,<xref rid="B27-ijms-23-14694" ref-type="bibr">27</xref>,<xref rid="B28-ijms-23-14694" ref-type="bibr">28</xref>,<xref rid="B60-ijms-23-14694" ref-type="bibr">60</xref>,<xref rid="B65-ijms-23-14694" ref-type="bibr">65</xref>,<xref rid="B66-ijms-23-14694" ref-type="bibr">66</xref>,<xref rid="B67-ijms-23-14694" ref-type="bibr">67</xref>]. In concert with these signal-dependent pathways, it was demonstrated that PLTs possess nuclear proteins. In a comprehensive PLT proteome analysis, 13% of all identified proteins were mapped to a nuclear location [<xref rid="B68-ijms-23-14694" ref-type="bibr">68</xref>]. PLTs utilize such proteins in established functions, as well as assigning alternative roles. Amongst other nuclear proteins, MKs distribute a functional spliceosome to PLTs [<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>]. In addition, nuclear receptors, including the receptors for sex steroids, glucocorticoids, peroxisome proliferator-activated receptors (PPAR)s, and retinoid X receptors (RXR)s were detected in PLTs, reported to bind their respective ligands, which induce PLT aggregation and activation (reviewed in [<xref rid="B69-ijms-23-14694" ref-type="bibr">69</xref>]). Unexpectedly, RAR was also demonstrated to be utilized by PLTs as a translational regulator [<xref rid="B28-ijms-23-14694" ref-type="bibr">28</xref>]. RAR is additionally employed in non-genomic activities by controlling actin cytoskeletal events [<xref rid="B31-ijms-23-14694" ref-type="bibr">31</xref>]. Nevertheless, there is paucity of data exploring and finally comparing the functional capacities of nuclear proteins in PLTs with their counterparts residing in MKs.</p><p>Here, we demonstrate for the first time, to the best of our knowledge, that <italic toggle="yes">NAP1L1</italic> mRNA is expressed in PLTs demonstrating potential transcript variants previously not detected in PLTs (<xref rid="ijms-23-14694-f001" ref-type="fig">Figure 1</xref> and <xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>, and <xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S1</xref>). Furthermore, we identify a protein interaction partner, PDC-E2, hitherto not characterized as being part of the NAP1L1 protein network (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>). Using septic PLTs, we were able to also demonstrate a dynamic protein expression pattern of NAP1L1 and its interaction partner PDC-E2, potentially resulting in altered pyruvate dehydrogenase complex (PDH) activity (<xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref> and <xref rid="ijms-23-14694-f006" ref-type="fig">Figure 6</xref>). In addition, using human MK cells, we were able to show that overexpression of NAP1L1 results in diminished proplatelet formation, and decreased PDC-E2-dependent PDH activity (<xref rid="ijms-23-14694-f007" ref-type="fig">Figure 7</xref> and <xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S3</xref>).</p><p>Our analyses of MKs and PLTs are also the first to examine <italic toggle="yes">NAP1L1</italic> transcript levels and protein expression pattern. While <italic toggle="yes">NAP1L1</italic> mRNA was previously detected in human PLTs [<xref rid="B49-ijms-23-14694" ref-type="bibr">49</xref>,<xref rid="B70-ijms-23-14694" ref-type="bibr">70</xref>], no in-depth analysis of potential transcript variants, changes in transcript levels, or specific protein expression or localization analysis was performed. Consistent with previous RNA sequencing results, we observed expression of <italic toggle="yes">NAP1L1</italic> mRNA using RNA sequencing techniques as well as confirmatory PCR approaches for PLT as well as MK samples, harvested throughout the MK culture period (<xref rid="ijms-23-14694-f001" ref-type="fig">Figure 1</xref>). Next, we designed a PCR primer pair spanning from exon 1 to exon 7. This enabled us to detect alternative transcript processing in MKs and PLTs resulting in <italic toggle="yes">NAP1L1</italic> transcript variant 5 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001330232.2">NM_001330232.2</ext-link>), which is devoid of exons 3 and 4 (<xref rid="ijms-23-14694-f002" ref-type="fig">Figure 2</xref>). This suggests that alternative splicing of <italic toggle="yes">NAP1L1</italic> occurs in MKs, and that PLTs get invested with such alternative transcripts by MKs. It is interesting to note that the transcript variant ratios did not change due to activation of PLTs using immobilized fibrinogen and thrombin (<xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S1</xref>), indicating that the alternative splicing process does not occur in the PLT cell bodies. <italic toggle="yes">NAP1L1</italic> transcript variant 5 is coding for the putative NAP1L1 isoform 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="NP_001317161.1">NP_001317161.1</ext-link>), which misses the N-terminal domain I. Domain I is mainly responsible for dimerization of NAP1L1 and mediating histone interaction [<xref rid="B54-ijms-23-14694" ref-type="bibr">54</xref>,<xref rid="B55-ijms-23-14694" ref-type="bibr">55</xref>,<xref rid="B71-ijms-23-14694" ref-type="bibr">71</xref>]. The presence of transcript variant 5, coding for a protein with a deleted functional domain, could be indicative of alternative protein functions of NAP1L1, besides the nucleosome assembly task in MKs and human PLTs. Taken together, these initial findings focused on <italic toggle="yes">NAP1L1</italic> transcripts demonstrated the presence of at least two <italic toggle="yes">NAP1L1</italic> transcript variants (1 and 5) and raised the question regarding whether NAP1L1 protein isoforms are located in MK and PLT cell bodies.</p><p>Using initial microscopy studies, we were able to demonstrate NAP1L1 protein in MKs, their proplatelet extensions (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>A), as well as in PLT cell bodies in a peri-granular pattern. While not performing detailed co-localization studies, the images from PLT studies support the finding that NAP1L1 protein does most likely not reside within the PLT granular compartment (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>B). Interestingly, NAP1L1 protein signals demonstrate minimal co-localization with nuclear/DNA co-staining signals when examining dividing MK-progenitors (<xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S2</xref>). Despite the known NAP-family members functions in DNA replication and cell proliferation [<xref rid="B72-ijms-23-14694" ref-type="bibr">72</xref>], and the previously described changing intracellular localization [<xref rid="B41-ijms-23-14694" ref-type="bibr">41</xref>], this could furthermore point towards an alternative cellular function assigned to NAP1L1 in the MK-PLT axis.</p><p>To confirm our microscopy data, we next examine NAP1L1 protein expression using Western blot analysis (<xref rid="ijms-23-14694-f003" ref-type="fig">Figure 3</xref>C,D). Our studies specifically demonstrate, for the first time, the presence of at least three different NAP1L1 isoforms in MKs and PLTs. This finding is consistent with the initial description of NAP1L1 and subsequent publications, which showed Western blot results indicating the existence of multiple NAP1L1 protein isoforms [<xref rid="B40-ijms-23-14694" ref-type="bibr">40</xref>,<xref rid="B43-ijms-23-14694" ref-type="bibr">43</xref>,<xref rid="B73-ijms-23-14694" ref-type="bibr">73</xref>]. To exclude cross-reactivity of the detection antibody, which could lead to false positive results, we performed peptide competition assays clearly demonstrating the specificity of our findings. The difference between observed and predicted molecular weight for NAP1L1 proteins, shown in our study, can be explained by potential post-translational modifications. NAP1L1, as part of the human NAP1L-family members, is known to contain C-terminal glutamylation sites, creating a reversible acidic C-terminal moiety, with the potential of switching between different protein functions [<xref rid="B55-ijms-23-14694" ref-type="bibr">55</xref>,<xref rid="B74-ijms-23-14694" ref-type="bibr">74</xref>,<xref rid="B75-ijms-23-14694" ref-type="bibr">75</xref>], but also resulting in changed migration during SDS-PAGE. This potential mechanism of post-translational protein and also functional modification was highlighted in a recent publication [<xref rid="B76-ijms-23-14694" ref-type="bibr">76</xref>]. Ye and colleagues demonstrated that MKs contain the enzymatic machinery necessary for performing and reversing polyglutamylations, namely tubulin tyrosine ligase-like family (TTLL) members TTLL4 and TTLL6, and cytosolic carboxypeptidase (CCP) 6. Therefore, differential protein isoform as well as specific post-translational modifications could be displayed by the detected NAP1L1 signals.</p><p>To explore additional NAP1L1 functions, besides the traditionally assigned roles, we wanted to further explore if new protein partners interacting with NAP1L1 could be identified in MKs and PLTs. Using co-IP techniques, we were able to reproduce a highly specific protein band, which could be identified and verified as PDC-E2, the protein product of <italic toggle="yes">DLAT</italic> (<xref rid="ijms-23-14694-f004" ref-type="fig">Figure 4</xref>). PDC-E2 is part of the mitochondrial multi-enzyme pyruvate dehydrogenase (PDH) complex (PDC), which converts pyruvate to acetyl-CoA. Recent studies indicated that PDC is also present in the nucleus and processes/catalyzes histone acetylation [<xref rid="B51-ijms-23-14694" ref-type="bibr">51</xref>,<xref rid="B77-ijms-23-14694" ref-type="bibr">77</xref>], and its subunit PDC-E2 can act as a nuclear transcriptional regulator [<xref rid="B78-ijms-23-14694" ref-type="bibr">78</xref>]. PDC-E2, also called dihydrolipoamide acetyltransferase, is the acceptor molecule for acetyl groups formed by the oxidative decarboxylation of pyruvate and transfers them to coenzyme A. Of note, in addition to its essential role in cellular metabolism, PDC-E2 is the key autoantigen in primary biliary cirrhosis (PBC) [<xref rid="B53-ijms-23-14694" ref-type="bibr">53</xref>]. Like many mitochondrial proteins, PDC-E2 is encoded by the nuclear genome and translated in the cytoplasm with an amino-terminal targeting sequence [<xref rid="B79-ijms-23-14694" ref-type="bibr">79</xref>,<xref rid="B80-ijms-23-14694" ref-type="bibr">80</xref>]. A direct interaction of NAP-family members with mitochondrial proteins is not unprecedented. Using a yeast two-hybrid system, Stelzl and colleagues created extensive protein&#8211;protein interaction maps, demonstrating that NAP1L1 interacted with dihydrolipoamide succinyltransferase (E2), a component of the mitochondrial 2-oxoglutarate dehydrogenase complex [<xref rid="B81-ijms-23-14694" ref-type="bibr">81</xref>]. Furthermore, Okada et al. [<xref rid="B56-ijms-23-14694" ref-type="bibr">56</xref>] demonstrated that NAP1L1 interacted with diacylglycerol kinase &#950; (DGK&#950;), which prohibited its nuclear import through blocking import carrier protein interaction. Therefore, in MKs, one might speculate if the NAP1L1&#8211;PDC-E2 interaction could serve a similar import&#8211;export control pathway.</p><p>Because of its clinical relevance, we decided to study NAP1L1 expression and potential function in a common, morbid, and often fatal systemic inflammatory disease&#8212;sepsis. We detected an increase in <italic toggle="yes">NAP1L1</italic> transcript in human PLTs, a finding which was paralleled by the protein expression data shown via immune detection of NAP1L1 (<xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref>). These findings pointed towards a dynamic regulation of NAP1L1 in septic PLTs, a clinical situation NAP1L1 was never studied under. Next, we examined PDC-E2 protein expression pattern in septic PLTs (<xref rid="ijms-23-14694-f006" ref-type="fig">Figure 6</xref>). PDC-E2 protein expression levels decreased in septic PLTs. However, PDH complex activity increased 13-fold over the metabolic activity measured in PLTs isolated from healthy individuals. This finding could be met with surprise since published studies indicate that the PDH complex is inhibited during sepsis, resulting in a switch from mitochondrial aerobic oxidation to cytoplasmic anaerobic glycolysis, a process known to contribute to the formation of lactic acid and intracellular acidosis, which can lead to intracellular Ca2<sup>+</sup> overload, mitochondrial membrane damage [<xref rid="B58-ijms-23-14694" ref-type="bibr">58</xref>,<xref rid="B82-ijms-23-14694" ref-type="bibr">82</xref>,<xref rid="B83-ijms-23-14694" ref-type="bibr">83</xref>]. Nevertheless, contrasting the general PDC-dependent metabolic reprogramming response in sepsis [<xref rid="B58-ijms-23-14694" ref-type="bibr">58</xref>,<xref rid="B84-ijms-23-14694" ref-type="bibr">84</xref>,<xref rid="B85-ijms-23-14694" ref-type="bibr">85</xref>], several studies demonstrated that mitochondrial oxygen consumption in PLTs is increased in septic patients, and closely related to their survival rate [<xref rid="B86-ijms-23-14694" ref-type="bibr">86</xref>,<xref rid="B87-ijms-23-14694" ref-type="bibr">87</xref>,<xref rid="B88-ijms-23-14694" ref-type="bibr">88</xref>]. Therefore, based on our observations, we speculate that due to its chaperone and potential shuttling function, NAP1L1 protein in septic PLTs could help stabilize the conformation of PDC-E2 molecules, and also mediate the known one-way transport [<xref rid="B89-ijms-23-14694" ref-type="bibr">89</xref>] into the mitochondrial compartment.</p><p>To confirm these results, the next step would be to genetically modify the target cells to demonstrate functional coherence. However, it is difficult to produce transfected and genetically modified uniform, high-quality human PLTs. Therefore, to further decipher the functional and mechanistic impact of NAP1L1&#8211;PDC-E2 interaction on the MK-PLT axis, we utilized a well-established PLT-surrogate MK culture model, as previously used by our laboratory [<xref rid="B7-ijms-23-14694" ref-type="bibr">7</xref>,<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>,<xref rid="B31-ijms-23-14694" ref-type="bibr">31</xref>]. To mimic increased NAP1L1 protein levels in septic PLTs, we used &#8220;liposome-based transfection&#8221; techniques (<xref rid="ijms-23-14694-f007" ref-type="fig">Figure 7</xref>A). Using this approach, NAP1L1 could be robustly overexpressed in the human MK culture system (<xref rid="ijms-23-14694-f007" ref-type="fig">Figure 7</xref>B). Transfected or vehicle-treated MKs were subsequently incubated with LPS, one of the major determinants in Gram-negative sepsis [<xref rid="B90-ijms-23-14694" ref-type="bibr">90</xref>]. It is important to note that LPS uses a well-established signaling pathway through TLR4, which is expressed by CD34<sup>+</sup>-derived MKs [<xref rid="B36-ijms-23-14694" ref-type="bibr">36</xref>]. In contrast to our septic PLT experiments, we observed that LPS treatment alone resulted in slightly decreased NAP1L1 expression levels. Performing a proplatelet formation (PPF) assay [<xref rid="B17-ijms-23-14694" ref-type="bibr">17</xref>], a standard read-out for MK function, we detected decreased PPF when NAP1L1 was overexpressed in MKs. In addition, it appeared that NAP1L1 protein overexpression and simulated septic conditions using LPS treatment, synergistically reduced PPF (<xref rid="ijms-23-14694-f007" ref-type="fig">Figure 7</xref>C,D). During their final stages, MKs produce PLTs by extending long cytoplasmic protrusions, designated proplatelets [<xref rid="B9-ijms-23-14694" ref-type="bibr">9</xref>], into sinusoidal blood vessels, a process coined PPF. While two independent, but interrelated cytoskeletal systems, actin filaments and tubulin subunits, provide the force leading to the shape changes associated with MK maturation and proplatelet formation [<xref rid="B10-ijms-23-14694" ref-type="bibr">10</xref>], it was elegantly shown that dynein-dependent microtubule sliding acts as the driving force for proplatelet elongation and PLT biogenesis [<xref rid="B11-ijms-23-14694" ref-type="bibr">11</xref>]. The rolling up of microtubules as they drive apart and extend the proplatelet is likely to be involved in forming the coils found in the proplatelet tips and the mature PLTs, called marginal band. The production of force with its synchronized cycles of microtubule binding and release, is energy consuming, using the hydrolysis of ATP [<xref rid="B12-ijms-23-14694" ref-type="bibr">12</xref>]. Therefore, we sought to examine NAP1L1&#8211;PDC-E2 interaction and PDH complex activity in MKs under simulated septic conditions, which might explain the decreased PPF. LPS-treated MKs demonstrated increased interactions between NAP1L1 and PDC-E2, and a significantly decreased PDH complex activity (<xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S3</xref>). These findings contrast our experimental results from septic PLTs. Nevertheless, opposite NAP1L1&#8211;PDC-E2 interaction levels, and PDH complex activity could potentially be explained by PLTs being anucleate, and therefore potentially using NAP1L1 protein in a different context than nucleated MKs. In PLTs, it seems more likely that NAP1L1 function could be defined and garnered towards chaperoning PDC-E2. Contrastingly, in MKs, NAP1L1 could help in the compartmentalization of PDC-E2, and therefore prohibiting the protein from entering its functional complex PDC, as it was shown for DGK&#950; [<xref rid="B56-ijms-23-14694" ref-type="bibr">56</xref>]. In sepsis, thrombocytopenia is closely related with clinical outcome. In this context, our MK data also complements previous reports demonstrating that one potential mechanism for low PLT counts in severely ill patients with advanced thrombocytopenia could be diminished thrombopoiesis [<xref rid="B91-ijms-23-14694" ref-type="bibr">91</xref>,<xref rid="B92-ijms-23-14694" ref-type="bibr">92</xref>]. Therefore, it is interesting to speculate about potential upstream signaling mechanisms triggering, and potentially enabling the NAP1L1&#8211;PDC-E2 protein interaction. In 1999, Cataldo and colleagues reported that Mpl (thrombopoietin, TPO), ligand of the Mpl-c receptor, regulates NAP1 family member expression in a rat bone marrow model [<xref rid="B93-ijms-23-14694" ref-type="bibr">93</xref>]. The authors were able to demonstrate that these NAP-related effects were limited to Mpl and could not be reproduced by other bone marrow growth factors (i.e., granulocate colony stimulating factor), which led to the conclusion of a cytokine specific effect. These results can be interpreted as a TPO-specific signaling pathway integrating sensing of PLT numbers, stimulation of progenitor cells by Mpl, and subsequent modulation of protein interactions. The involvement of the Mpl (TPO) signaling pathway in the newly discovered NAP1L1&#8211;PDC-E2 protein interaction will therefore be a focus of future studies.</p><p>The presented study was data driven and performed under best research practice. Nevertheless, there are some limitations to this study. Since the generation of the presented data, CRISPR-Cas9 technique has been developed for rapid genetic manipulation of MKs [<xref rid="B62-ijms-23-14694" ref-type="bibr">62</xref>]. For future studies we would propose to use such an approach for further dissecting the mechanistic function of PDC-E2 in MKs in greater detail. We appreciate the descriptive character of our study; however, this is the first report of NAP1L1 interacting specifically with a previously unrecognized partner protein. Therefore, we recognize that our findings should be extended in future studies, potentially complemented by in vivo work using relevant mouse models.</p><p>In conclusion, our data demonstrate NAP1L1 expression in human PLTs and MKs. This is the first time that expression of different <italic toggle="yes">NAP1L1</italic> transcript variants, and protein isoform was confirmed in such cells. Our findings demonstrate, for the first time, that NAP1L1 interacts with PDC-E2, a subunit of the PDH complex. The PDH complex acts as an energy homeostat bridging glycolysis to energy production, and its function gets modulated during sepsis, carbohydrate metabolism away from mitochondrial oxidation. Our data shed new light on such processes taking place in PLTs and MKs during sepsis. At the moment, however, it remains undetermined how NAP1L1 functions are coordinated when comparing nucleated versus anucleate state. Nevertheless, our results support the conclusion of differential functions of NAP1L1 in MKs and PLTs during systemic inflammation and open a new avenue of sepsis research focused on the MK-PLT axis.</p></sec><sec id="sec4-ijms-23-14694"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-23-14694"><title>4.1. Reagents and Antibodies</title><p>The following reagents and antibodies were used for microscopy, Western blot, and co-IP studies as described below: Paraformaldehyde (PFA 4% [2% final]), Alexa Fluor&#174; 555 conjugate of wheat germ agglutinin (WGA, 1:1000; Thermo Fisher Scientific, Waltham, MA, USA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="W32464">W32464</ext-link>), Alexa Fluor&#174; 647 conjugate of phalloidin (Thermo Fisher Scientific, A22287), 4&#8242;,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI, Thermo Fisher Scientific, D1306), mouse anti-NAP1L1 antibody (abcam, Cambridge, MA, USA, ab58677), rabbit anti-NAP1L1 (abcam, ab33076), rabbit anti-Pyruvate dehydrogenase complex component E2 (PDC-E2, ODP2; abcam, ab 66511), rabbit anti-beta tubulin (abcam, ab232361), mouse anti-tubulin (MilliporeSigma, Billerica, MA, USA, T-5293), mouse anti-ACTB/actin HRP-conjugated (abcam, ab20272), and NAP1L1 blocking peptide (abcam, ab22418). Secondary HRP-conjugated antibodies, and secondary antibodies conjugated to Alexa Fluor&#174; 488 and 546 were purchased from Thermo Fisher Scientific (G-21040, G-21234, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="S11223">S11223</ext-link>, A-11001, A-11008, A-21422, A-21428).</p></sec><sec sec-type="subjects" id="sec4dot2-ijms-23-14694"><title>4.2. Septic Patients</title><p>Patients were selected for meeting consensus criteria for sepsis [<xref rid="B94-ijms-23-14694" ref-type="bibr">94</xref>], and enrolled within 48 h of ICU admission (n = 9, and 17, for septic and healthy, respectively).</p></sec><sec id="sec4dot3-ijms-23-14694"><title>4.3. PLT Isolation and Culture</title><p>PLTs used for the described studies were freshly isolated. PLTs were leukocyte-reduced and isolated, as previously described to yield a highly purified population of cells with &lt;1 leukocyte per 10<sup>7</sup> PLTs [<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>,<xref rid="B66-ijms-23-14694" ref-type="bibr">66</xref>]. In addition, PLT activation during centrifugation steps was mitigated by the addition of 100 nM prostaglandin E1 (PGE-1) before each centrifugation step. Depleted PLTs were resuspended at 1 &#215; 10<sup>8</sup>/mL in a serum-free M199 medium (Thermo Fisher Scientific, 11150067), placed in round-bottom polypropylene tubes, and incubated, where indicated, in a 37 &#176;C humidified incubator at 5% CO<sub>2</sub> for different time points. In select studies, PLTs were placed on immobilized fibrinogen and stimulated with thrombin (factor IIa), as previously described [<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>].</p></sec><sec id="sec4dot4-ijms-23-14694"><title>4.4. CD34<sup>+</sup>-Derived MKs</title><p>CD34<sup>+</sup> hematopoietic progenitor cells were isolated from human umbilical cord blood and differentiated into proplatelet-producing MKs, as previously described [<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>,<xref rid="B31-ijms-23-14694" ref-type="bibr">31</xref>].</p></sec><sec id="sec4dot5-ijms-23-14694"><title>4.5. RNA Isolation</title><p>MKs or PLTs were lysed in TRIzol (Thermo Fisher Scientific, 15596026), and RNA isolation was performed, as previously described [<xref rid="B23-ijms-23-14694" ref-type="bibr">23</xref>,<xref rid="B24-ijms-23-14694" ref-type="bibr">24</xref>]. All RNA samples were DNase treated using the TURBO DNA-free Kit (Thermo Fisher Scientific, AM 1907) per manufacturer&#8217;s protocol.</p></sec><sec id="sec4dot6-ijms-23-14694"><title>4.6. Next Generation RNA-Sequencing</title><p>For next-generation RNA-sequencing (RNA-seq), 1 &#215; 10<sup>9</sup> isolated PLTs were carefully lysed in TRIzol and DNase treated, as described above. Total RNA was isolated, as previously described [<xref rid="B22-ijms-23-14694" ref-type="bibr">22</xref>,<xref rid="B25-ijms-23-14694" ref-type="bibr">25</xref>,<xref rid="B31-ijms-23-14694" ref-type="bibr">31</xref>,<xref rid="B49-ijms-23-14694" ref-type="bibr">49</xref>,<xref rid="B95-ijms-23-14694" ref-type="bibr">95</xref>]. An Agilent bio-analyzer 2100 (Agilent, Santa Clara, CA, USA) was used to quantify the amount and quality of the total RNA. RNA Integrity Number (RIN) scores were similar between all samples. RNA-seq libraries were prepared with TruSeq V2 with oligo-dT selection (Illumina, San Diego, CA, USA, RS-122-2001). Reads were aligned (Novoalign) to the reference genome at the time of these studies (GRCh37/hg19) and a pseudo-transcriptome containing splice junctions. The Deseq2 analysis package was used to assign reads to composite transcripts (one per gene) and quantitate reads per kilobase of transcript per million mapped reads/RPKMs.</p></sec><sec id="sec4dot7-ijms-23-14694"><title>4.7. PCR Studies</title><p>To determine <italic toggle="yes">NAP1L1</italic> mRNA expression pattern in human PLTs and CD34<sup>+</sup>-derived MKs, primers spanning exon 8&#8211;10 (248 bp product) of <italic toggle="yes">NAP1L1</italic> (NAP1L1_1012_forward 5&#8242;-AGT GAA GTT CTC AGA TGC TGG-3&#8242; and NAP1L1_1259_reverse 5&#8242;-CAC GTC CCT TGT GTT TCT GC-3&#8242;) and primers spanning exon 1/2&#8211;7/8 (588 bp and 399 bp products) of <italic toggle="yes">NAP1L1</italic> (NAP1L1_460_forward 5&#8242;-AGT CGC CGA TAT TTG GAG TTC T-3&#8242; and NAP1L1_1047_reverse 5&#8242;-TCC TGA ACC ATA TCA CTG AGC A-3&#8242;) were used (in-house synthesis) and PCR was performed. Loading control primers detecting <italic toggle="yes">B2M</italic> mRNA were used on paralleling samples (B2M_34_forward 5&#8242;-AGC TGA CAG CAT TCG GGC-3&#8242; and B2M_333_reverse GTG GGG GTG AAT TCA GTG TAG T-3&#8242;). Annealing temperatures were selected as follows: primers spanning exon 8&#8211;10 of <italic toggle="yes">NAP1L1</italic>, 60 &#176;C; primers spanning exon 1/2&#8211;7/8 of <italic toggle="yes">NAP1L1</italic>, 58 &#176;C; primers detecting <italic toggle="yes">B2M,</italic> 57 &#176;C.</p></sec><sec id="sec4dot8-ijms-23-14694"><title>4.8. Immunocytochemistry</title><p>On day 13 of the CD34<sup>+</sup>- differentiation process, MKs were placed on fibrinogen-coated chamber slides to induce proplatelet formation, fixed (PFA), permeabilized with 0.1% Triton X-100 (Thermo Fisher Scientific, AC327372500) for 5 min at room temperature (RT), and subsequently incubated with IgG, or an antibody against NAP1L1, and anti-b-tubulin antibody for co-staining purposes, overnight at 4 &#176;C. The next day, cells were incubated with secondary antibodies conjugated to Alexa Fluor<sup>&#174;</sup> 488 or 546, followed by co-staining using DAPI for nuclear localization. In select studies (see <xref rid="app1-ijms-23-14694" ref-type="app">Supplementary Figure S2</xref>), MKs were incubated with IgG or an antibody against NAP1L1, followed by co-staining for sialic acids/glycoproteins (in cell membranes/granular content) and the actin cytoskeleton using WGA or phalloidin, respectively.</p><p>Freshly isolated PLTs were fixed in suspension using PFA, permeabilized with 0.1% Triton X-100 (Thermo Fisher Scientific, AC327372500) for 5 min at room temperature (RT) and subsequently layered onto VECTABOND<sup>TM</sup> (Vector Laboratories, Burlingame, CA, USA, SP1800) coated coverslips using a cytospin centrifuge (Shandon Cytospin, Thermo Fisher Scientific). Cells were incubated with IgG (to control for specificity of signal) or an antibody against NAP1L1 overnight at 4 &#176;C. Cells were subsequently incubated with secondary antibodies conjugated to Alexa Fluor<sup>&#174;</sup> 488 or 546. Sialic acids/glycoproteins (in cell membranes/granular content) were co-stained using WGA.</p></sec><sec id="sec4dot9-ijms-23-14694"><title>4.9. Microscopy and Image Analysis</title><p>Fluorescence microscopy and high-resolution confocal reflection microscopy were performed using an Olympus IX81, FV300 (Olympus, Melville, NY) confocal-scanning microscope equipped with a 60&#215;/1.42 NA oil objective for viewing PLTs. An Olympus FVS-PSU/IX2-UCB camera and scanning unit and Olympus Fluoview FV 300 image acquisition software version 5.0 were used for recording. In addition, an EVOS FL Auto Cell imaging system with an integrated dual camera system, system-specific software and equipped with a 609/1.42 NA oil objective was used. Monochrome 16-bit images were further analyzed, and changes were quantified using Adobe Photoshop CS6, ImageJ (NIH), and CellProfiler (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.cellprofiler.org">www.cellprofiler.org</uri> (last accessed on 1 October 2022)) [<xref rid="B96-ijms-23-14694" ref-type="bibr">96</xref>]. Analysis of images presented in <xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref>B was performed with a customized CellProfiler analysis set. In brief, raw images were automatically analyzed to minimize observer bias. The following software parameters were introduced: threshold method&#8212;otsu (this approach calculates the threshold separating three classes of pixels by minimizing the variance within each class); threshold correction factor&#8212;2.5 (a value &gt; 1 makes the threshold more stringent, since the otsu method will give a slightly biased threshold if a larger percentage of the image is covered with positive signal).</p></sec><sec id="sec4dot10-ijms-23-14694"><title>4.10. Protein Expression Studies</title><p>All samples were normalized for starting cell concentrations. PLTs were lysed in Laemmli-buffer, and samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and examined by western analysis for NAP1L1 or PDC-E2/ODP2 expression patterns. Subsequently, proteins were detected by enhanced chemiluminescence (ECL; Thermo Fisher Scientific, 32132). Linear range of detection was assured by using the saturation detection mode of the myECL Imager (Thermo Fisher Scientific, Waltham, MA, USA). For select studies a peptide competition assay was performed. In brief, a PVDF membrane loaded equally was split in half, and probed using anti-NAP1L1 antibodies pre-incubated with or without specific NAP1L1 peptide fragment (blocking peptide; incubated for 1 h at 37 &#176;C in blocking buffer (TBS, Tween, non-fat dry milk)). Specific protein expression was normalized using ACTB/actin or b-tubulin expression and quantified using ImageJ (NIH).</p></sec><sec id="sec4dot11-ijms-23-14694"><title>4.11. Co-Immunoprecipitation Studies</title><p>For all modified protein co-IP studies, the Universal Magnetic Co-IP Kit (Active Motif, Carlsbad, CA, USA, 54002) was used according to the manufacturer&#8217;s protocol; however, magnetic beads were replaced using protein G magnetic beads specifically suited for immunoprecipitation (Dynabeads; Thermo Fisher Scientific, 10003D). In brief, 2 &#215; 10<sup>9</sup> total PLTs, or MKs were first pelleted and washed in PBS supplemented with phosphatase and deacetylase inhibitors. Cells were then lysed in 300 &#181;L of the provided whole-cell lysis buffer and an additional protease inhibitor cocktail supplied by the manufacturer. The magnetic beads used for the IP reaction were either incubated with the antibody of interest (anti-NAP1L1) or the respective IgG control for 30 min at RT. Co-IP was performed using the prepared beads, the supplied buffer and the PLT cell lysate from 0.6 &#215; 10<sup>9</sup> PLTs or MKs with constant rotation for 4 h at 4 &#176;C. The IP complexes were isolated and cleaned by placing the samples on a magnetic stand and performing repeated washes with the provided wash-buffer. Finally, each bead pellet was resuspended in 20 &#181;L of Laemmli-buffer and heated to 99 &#176;C for 3 min before being separated using SDS-PAGE or Western blot techniques, as described above. For mass spectrometry purposes, gels were directly stained using standard MS-compatible silver staining.</p></sec><sec id="sec4dot12-ijms-23-14694"><title>4.12. Mass Spectrometry</title><p>Protein bands of interest were manually picked using standard techniques to ensure minimal contamination with human skin particles. Excised protein bands were de-stained, extracted proteins were trypsin digested per established standard methods, and analyzed by an LTQ Orbitrap Velos MS coupled with a nano-acquity UPLC system (Thermo Fisher Scientific, and Waters Corporation, Milford, MA, USA) mass spectrometer with electro-spray ionization at the University of Greifswald at the Institute of Functional Genome Research. Repeat MS/MS fragmentation was controlled by applying dynamic exclusion using one repeat count, a repeat duration of 30 s, an exclusion list size of 500, and an exclusion duration of 60 s. Peptides were identified using SEQUEST [<xref rid="B97-ijms-23-14694" ref-type="bibr">97</xref>], and analyzed using Scaffold (v.27 r.11, Proteome Software, Portland OR, USA) and the peptide/protein prophet algorithm [<xref rid="B98-ijms-23-14694" ref-type="bibr">98</xref>], which was linked to the Uni-PROT/SWISS-PROT (human_v2014_02) data base, resulting in total spectrum counts per identified protein. Analysis settings included a peptide mass tolerance of 5 ppm, fragment ion tolerance of 0.5 Da, monoisotopic masses and trypsin cleavage (maximum two missed cleavages). Protein identifications were accepted when <italic toggle="yes">p</italic> &lt; 0.05 after adjustment using the Scaffold mass correction, resulting in a false discovery rate of &lt;1%.</p></sec><sec id="sec4dot13-ijms-23-14694"><title>4.13. PDH Activity Assay</title><p>All samples prepared and used for the performance of the PDH activity assay were normalized by cell number. The assay was conducted following the manufacturer&#8217;s protocol (abcam, ab109882). In brief, 50 &#181;L of each sample was used and an equal volume of blocking fluid was added to a 96-well plate. The dipstick was dipped into the well and the sample allowed to wick onto the dipstick for 60 min. The dipstick was washed, and an activity buffer was added for 20 min. Since the activity reaction is an endpoint reaction, each dipstick was exposed for precisely monitored equal exposure times. The reaction was stopped using ddH<sub>2</sub>O. The results were documented using imaging scan techniques, and the signal was quantified using ImageJ (NIH).</p></sec><sec id="sec4dot14-ijms-23-14694"><title>4.14. NAP1L1 In Vitro Transcription</title><p>NAP1L1 was in vitro transcribed using a commercially available NAP1L1 expression plasmid (Origene, Rockville, MD, USA, RC201851) containing a T7 promotor for seamless in vitro transcription reactions. The linearized plasmid template, using the Pme I restriction site, was introduced into the in vitro transcription reaction (Thermo Fisher Scientific, AM 1345). The selected in vitro transcription kit, mMESSAGE mMACHINE&#8482; T7 ULTRA Transcription Kit, was optimized to synthesize large amounts of efficiently and correctly capped mRNA, including a final poly(A) tailing step. The final mRNA product was subsequently isolated and purified using the MEGAclear kit (Thermo Fisher Scientific, AM 1908), and stored at &#8722;80 &#176;C until used for transfection reactions.</p></sec><sec id="sec4dot15-ijms-23-14694"><title>4.15. NAP1L1 Transfection and Overexpression</title><p>CD34<sup>+</sup>-derived MKs were transfected on day 12 of the culture and were placed on immobilized fibrinogen on day 14 to induce proplatelet formation. Cells were transfected using Lipofectamine&#8482; MessengerMAX&#8482; Transfection Reagent per the manufacturer&#8217;s standard protocol. In brief, MKs on day 12 of the culture and differentiation course were used for the experiment. MesengerMAX reagent was diluted in Opti-MEM Medium (1:16.6). Next, mRNA master mixes were prepared by adding 1 &#181;g of in vitro transcribed capped and poly(A)-tailed NAP1L1 mRNA, or its vehicle to 25 &#181;L Opti-MEM Medium. The diluted mRNA was subsequently added to the dilute MessengerMAX, as prepared above, and incubated for 5 min. at room temperature. Transfection mixes were added to cells and incubated over night at 37 &#176;C and 5% CO<sub>2</sub>. Cells were treated overnight with LPS 100 ng/mL or its vehicle, lysed in Laemmli-buffer, and samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and examined by western analysis for NAP1L1 over-expression patterns.</p></sec><sec id="sec4dot16-ijms-23-14694"><title>4.16. Proplatelet Formation Assay</title><p>On day 13, the proplatelet forming (PPF) MK, defined as displaying at least one filamentous pseudopod, were scored by microscopy blinded as to experimental group, as previously described [<xref rid="B17-ijms-23-14694" ref-type="bibr">17</xref>]. The percentage of PPF MK was calculated as the number of PPF MK compared to the total number of round cultured cells analyzed. An average of 200 cells were counted per condition.</p></sec><sec id="sec4dot17-ijms-23-14694"><title>4.17. Statistical Analyses</title><p>The mean &#177; SEM was determined for each variable. Student <italic toggle="yes">t</italic>-tests or ANOVA (where multiple groups were compared) was used to identify differences among two or multiple experimental groups, respectively (GraphPad Prism v9.1.0). If significant differences were found, Tukey&#8217;s multiple comparison test was used as recommended to determine the location of the difference (applicable for ANOVA). Basic science data were also examined for normality using Shapiro&#8211;Wilk and Kolmogorov&#8211;Smirnov tests. Non-parametric distribution was detected for the data presented in <xref rid="ijms-23-14694-f005" ref-type="fig">Figure 5</xref>E, and data was analyzed using Mann&#8211;Whitney-U/Wilcoxon Signed Rank test. For all analyses, <italic toggle="yes">p</italic>-value &lt; 0.05 was considered significant, and exact <italic toggle="yes">p</italic>-values are indicated for each figure.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank Chris K. Rodesch of the University of Utah Cell Imaging Core, Anni Schumacher at the University of Greifswald for excellent technical assistance, and Matthew Rondina for collaboration and sample sharing. We also thank Diana Lim for preparation of the figures, critical comments, and consultation regarding effective display of the images.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-ijms-23-14694"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms232314694/s1">https://www.mdpi.com/article/10.3390/ijms232314694/s1</uri>, Figure S1: PLT activation does not change NAP1L1 expression pattern, Figure S2: MKs undergoing anaphase showed reduced NAP1L1 association with condensed chromosomes, Figure S3: NAP1L1-PDC-E2 interaction and pyruvate dehydrogenase complex activity are increased in MKs when exposed to agonist being present during sepsis.</p><supplementary-material id="ijms-23-14694-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-23-14694-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>M.F. and H.S. conceived, designed and performed the experiments. M.F. and H.S. analyzed the data. M.F. and H.S. contributed reagents/materials/analysis tools. M.F. and H.S. wrote and reviewed the paper. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of The University of Utah (IRB#000392 and IRB#00046263), and the University of Greifswald (BB 047/13 and BB 111/13).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-23-14694"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichtman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Santillo</surname><given-names>P.A.</given-names></name></person-group><article-title>Parasinusoidal location of megakaryocytes in marrow: A determinant of platelet release</article-title><source>Am. J. Hematol.</source><year>1978</year><volume>4</volume><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1002/ajh.2830040402</pub-id><pub-id pub-id-type="pmid">717392</pub-id></element-citation></ref><ref id="B2-ijms-23-14694"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefrancais</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ortiz-Munoz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Caudrillier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mallavia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sayah</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Headley</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>David</surname><given-names>T.</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors</article-title><source>Nature</source><year>2017</year><volume>544</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/nature21706</pub-id><pub-id pub-id-type="pmid">28329764</pub-id><pub-id pub-id-type="pmcid">PMC5663284</pub-id></element-citation></ref><ref id="B3-ijms-23-14694"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>The biogenesis of platelets from megakaryocyte proplatelets</article-title><source>J. Clin. Investig.</source><year>2005</year><volume>115</volume><fpage>3348</fpage><lpage>3354</lpage><pub-id pub-id-type="doi">10.1172/JCI26891</pub-id><pub-id pub-id-type="pmid">16322779</pub-id><pub-id pub-id-type="pmcid">PMC1297261</pub-id></element-citation></ref><ref id="B4-ijms-23-14694"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machlus</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>The incredible journey: From megakaryocyte development to platelet formation</article-title><source>J. Cell Biol.</source><year>2013</year><volume>201</volume><fpage>785</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1083/jcb.201304054</pub-id><pub-id pub-id-type="pmid">23751492</pub-id><pub-id pub-id-type="pmcid">PMC3678154</pub-id></element-citation></ref><ref id="B5-ijms-23-14694"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machlus</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Thon</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Interpreting the developmental dance of the megakaryocyte: A review of the cellular and molecular processes mediating platelet formation</article-title><source>Br. J. Haematol.</source><year>2014</year><volume>165</volume><fpage>227</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1111/bjh.12758</pub-id><pub-id pub-id-type="pmid">24499183</pub-id></element-citation></ref><ref id="B6-ijms-23-14694"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Franks</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Manne</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Supiano</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>Granzyme A in Human Platelets Regulates the Synthesis of Proinflammatory Cytokines by Monocytes in Aging</article-title><source>J. Immunol.</source><year>2018</year><volume>200</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700885</pub-id><pub-id pub-id-type="pmid">29167233</pub-id><pub-id pub-id-type="pmcid">PMC5736423</pub-id></element-citation></ref><ref id="B7-ijms-23-14694"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hottz</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Manne</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Washington</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Hunter-Mellado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eustes</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Human megakaryocytes possess intrinsic anti-viral immunity through regulated induction of IFITM3</article-title><source>Blood</source><year>2019</year><volume>133</volume><fpage>2013</fpage><lpage>2026</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-09-873984</pub-id><pub-id pub-id-type="pmid">30723081</pub-id><pub-id pub-id-type="pmcid">PMC6509546</pub-id></element-citation></ref><ref id="B8-ijms-23-14694"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Grissom</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Beesley</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kosaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Manne</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Krauel</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Sepsis alters the transcriptional and translational landscape of human and murine platelets</article-title><source>Blood</source><year>2019</year><volume>134</volume><fpage>911</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1182/blood.2019000067</pub-id><pub-id pub-id-type="pmid">31366617</pub-id><pub-id pub-id-type="pmcid">PMC6753624</pub-id></element-citation></ref><ref id="B9-ijms-23-14694"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Massberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goerge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Shivdasani</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Dynamic visualization of thrombopoiesis within bone marrow</article-title><source>Science</source><year>2007</year><volume>317</volume><fpage>1767</fpage><lpage>1770</lpage><pub-id pub-id-type="doi">10.1126/science.1146304</pub-id><pub-id pub-id-type="pmid">17885137</pub-id></element-citation></ref><ref id="B10-ijms-23-14694"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kahle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Galjart</surname><given-names>N.</given-names></name><name name-style="western"><surname>Drabek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shivdasani</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>4076</fpage><lpage>4085</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-06-2204</pub-id><pub-id pub-id-type="pmid">16118321</pub-id><pub-id pub-id-type="pmcid">PMC1895246</pub-id></element-citation></ref><ref id="B11-ijms-23-14694"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bender</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thon</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Ehrlicher</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mazutis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deschmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sola-Visner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>J.H.</given-names></name></person-group><article-title>Microtubule sliding drives proplatelet elongation and is dependent on cytoplasmic dynein</article-title><source>Blood</source><year>2015</year><volume>125</volume><fpage>860</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-09-600858</pub-id><pub-id pub-id-type="pmid">25411426</pub-id><pub-id pub-id-type="pmcid">PMC4311231</pub-id></element-citation></ref><ref id="B12-ijms-23-14694"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>A.P.</given-names></name></person-group><article-title>Review: Structure and mechanism of the dynein motor ATPase</article-title><source>Biopolymers</source><year>2016</year><volume>105</volume><fpage>557</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1002/bip.22856</pub-id><pub-id pub-id-type="pmid">27062277</pub-id><pub-id pub-id-type="pmcid">PMC4879348</pub-id></element-citation></ref><ref id="B13-ijms-23-14694"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koupenova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corkrey</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>J.E.</given-names></name></person-group><article-title>Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis</article-title><source>Circ. Res.</source><year>2018</year><volume>122</volume><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310795</pub-id><pub-id pub-id-type="pmid">29348254</pub-id><pub-id pub-id-type="pmcid">PMC5777300</pub-id></element-citation></ref><ref id="B14-ijms-23-14694"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Semple</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Freedman</surname><given-names>J.</given-names></name></person-group><article-title>Platelets and the immune continuum</article-title><source>Nat. Rev. Immunol.</source><year>2011</year><volume>11</volume><fpage>264</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/nri2956</pub-id><pub-id pub-id-type="pmid">21436837</pub-id></element-citation></ref><ref id="B15-ijms-23-14694"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kraiss</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name></person-group><article-title>Protein synthesis by platelets: Historical and new perspectives</article-title><source>J. Thromb. Haemost.</source><year>2009</year><volume>7</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2008.03211.x</pub-id><pub-id pub-id-type="pmid">18983498</pub-id><pub-id pub-id-type="pmcid">PMC3027201</pub-id></element-citation></ref><ref id="B16-ijms-23-14694"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name></person-group><article-title>Signal-dependent protein synthesis by activated platelets: New pathways to altered phenotype and function</article-title><source>Arter. Thromb. Vasc. Biol.</source><year>2008</year><volume>28</volume><fpage>s17</fpage><lpage>s24</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.107.160218</pub-id><pub-id pub-id-type="pmcid">PMC2594008</pub-id><pub-id pub-id-type="pmid">18296586</pub-id></element-citation></ref><ref id="B17-ijms-23-14694"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatlekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Basak</surname><given-names>I.</given-names></name><name name-style="western"><surname>Edelstein</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Lindsey</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Sola-Visner</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Anti-apoptotic BCL2L2 increases megakaryocyte proplatelet formation in cultures of human cord blood</article-title><source>Haematologica</source><year>2019</year><volume>104</volume><fpage>2075</fpage><lpage>2083</lpage><pub-id pub-id-type="doi">10.3324/haematol.2018.204685</pub-id><pub-id pub-id-type="pmid">30733267</pub-id><pub-id pub-id-type="pmcid">PMC6886406</pub-id></element-citation></ref><ref id="B18-ijms-23-14694"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koliopoulou</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Montenont</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Javan</surname><given-names>H.</given-names></name><name name-style="western"><surname>McKellar</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Drakos</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Selzman</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>Longitudinal assessment of the platelet transcriptome in advanced heart failure patients following mechanical unloading</article-title><source>Platelets</source><year>2020</year><volume>31</volume><fpage>952</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1080/09537104.2020.1714573</pub-id><pub-id pub-id-type="pmid">31934818</pub-id><pub-id pub-id-type="pmcid">PMC7358121</pub-id></element-citation></ref><ref id="B19-ijms-23-14694"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rondina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Voora</surname><given-names>D.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bhatlekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Eustes</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Montenont</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Longitudinal RNA-seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet SELP Splice QTL</article-title><source>Circ. Res.</source><year>2019</year><volume>126</volume><fpage>501</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315215</pub-id><pub-id pub-id-type="pmid">31852401</pub-id><pub-id pub-id-type="pmcid">PMC7323475</pub-id></element-citation></ref><ref id="B20-ijms-23-14694"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name></person-group><article-title>Platelet mRNA: The meaning behind the message</article-title><source>Curr. Opin. Hematol.</source><year>2012</year><volume>19</volume><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1097/MOH.0b013e328357010e</pub-id><pub-id pub-id-type="pmid">22814651</pub-id><pub-id pub-id-type="pmcid">PMC3670814</pub-id></element-citation></ref><ref id="B21-ijms-23-14694"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Lindemann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Kraiss</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Mahoney</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name></person-group><article-title>Change in protein phenotype without a nucleus: Translational control in platelets</article-title><source>Semin. Thromb. Hemost.</source><year>2004</year><volume>30</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1055/s-2004-833484</pub-id><pub-id pub-id-type="pmid">15354270</pub-id></element-citation></ref><ref id="B22-ijms-23-14694"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mackman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grissom</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name></person-group><article-title>The septic milieu triggers expression of spliced tissue factor mRNA in human platelets</article-title><source>J. Thromb. Haemost.</source><year>2011</year><volume>9</volume><fpage>748</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2011.04208.x</pub-id><pub-id pub-id-type="pmid">21255247</pub-id><pub-id pub-id-type="pmcid">PMC3071458</pub-id></element-citation></ref><ref id="B23-ijms-23-14694"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Bunting</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lindemann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yost</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Rubner</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Albertine</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Escaping the nuclear confines: Signal-dependent pre-mRNA splicing in anucleate platelets</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.06.015</pub-id><pub-id pub-id-type="pmid">16096058</pub-id><pub-id pub-id-type="pmcid">PMC4401993</pub-id></element-citation></ref><ref id="B24-ijms-23-14694"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Foulks</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Denis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Risenmay</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Buerke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tilley</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Kraiss</surname><given-names>L.W.</given-names></name><etal/></person-group><article-title>Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets</article-title><source>J. Exp. Med.</source><year>2006</year><volume>203</volume><fpage>2433</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1084/jem.20061302</pub-id><pub-id pub-id-type="pmid">17060476</pub-id><pub-id pub-id-type="pmcid">PMC2118136</pub-id></element-citation></ref><ref id="B25-ijms-23-14694"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Chappaz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corduan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manne</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Wurtzel</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Goldfinger</surname><given-names>L.E.</given-names></name><etal/></person-group><article-title>Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets</article-title><source>Blood</source><year>2016</year><volume>127</volume><fpage>1743</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-07-661371</pub-id><pub-id pub-id-type="pmid">26773046</pub-id><pub-id pub-id-type="pmcid">PMC4825412</pub-id></element-citation></ref><ref id="B26-ijms-23-14694"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Schumann</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Thorack</surname><given-names>U.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Manne</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>Endogenous LINE-1 (Long Interspersed Nuclear Element-1) Reverse Transcriptase Activity in Platelets Controls Translational Events Through RNA-DNA Hybrids</article-title><source>Arter. Thromb. Vasc. Biol.</source><year>2018</year><volume>38</volume><fpage>801</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.310552</pub-id><pub-id pub-id-type="pmcid">PMC5864535</pub-id><pub-id pub-id-type="pmid">29301786</pub-id></element-citation></ref><ref id="B27-ijms-23-14694"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name></person-group><article-title>Assessing protein synthesis by platelets</article-title><source>Methods Mol. Biol.</source><year>2012</year><volume>788</volume><fpage>141</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">22130706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-61779-307-3_11</pub-id></element-citation></ref><ref id="B28-ijms-23-14694"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>Retinoic acid receptor-alpha regulates synthetic events in human platelets</article-title><source>J. Thromb. Haemost.</source><year>2017</year><volume>15</volume><fpage>2408</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1111/jth.13861</pub-id><pub-id pub-id-type="pmid">28981191</pub-id></element-citation></ref><ref id="B29-ijms-23-14694"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Traves</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Paul-Clark</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bishop-Bailey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J.A.</given-names></name></person-group><article-title>Role of nuclear receptor signaling in platelets: Antithrombotic effects of PPARbeta</article-title><source>FASEB J.</source><year>2006</year><volume>20</volume><fpage>326</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1096/fj.05-4395fje</pub-id><pub-id pub-id-type="pmid">16368717</pub-id></element-citation></ref><ref id="B30-ijms-23-14694"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Spinelli</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Murant</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Taubman</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>R.P.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles</article-title><source>Thromb. Haemost.</source><year>2008</year><volume>99</volume><fpage>86</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">18217139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1160/TH07-05-0328</pub-id><pub-id pub-id-type="pmcid">PMC2754860</pub-id></element-citation></ref><ref id="B31-ijms-23-14694"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Freitag</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pluthero</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Kahr</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kraiss</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Franks</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name></person-group><article-title>Non-genomic activities of retinoic acid receptor alpha control actin cytoskeletal events in human platelets</article-title><source>J. Thromb. Haemost.</source><year>2016</year><volume>14</volume><fpage>1082</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1111/jth.13281</pub-id><pub-id pub-id-type="pmid">26848712</pub-id><pub-id pub-id-type="pmcid">PMC5497578</pub-id></element-citation></ref><ref id="B32-ijms-23-14694"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bouslama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Machlus</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Martinez-Bonet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Wactor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nelson-Maney</surname><given-names>N.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets</article-title><source>eLife</source><year>2019</year><volume>8</volume><fpage>e44031</fpage><pub-id pub-id-type="doi">10.7554/eLife.44031</pub-id><pub-id pub-id-type="pmid">31042146</pub-id><pub-id pub-id-type="pmcid">PMC6494422</pub-id></element-citation></ref><ref id="B33-ijms-23-14694"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Massberg</surname><given-names>S.</given-names></name></person-group><article-title>Thrombosis as an intravascular effector of innate immunity</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><fpage>34</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/nri3345</pub-id><pub-id pub-id-type="pmid">23222502</pub-id></element-citation></ref><ref id="B34-ijms-23-14694"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2204</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02204</pub-id><pub-id pub-id-type="pmid">31572400</pub-id><pub-id pub-id-type="pmcid">PMC6753373</pub-id></element-citation></ref><ref id="B35-ijms-23-14694"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Compagnon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Poette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gratacap</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Lapebie</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Voisin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Minville</surname><given-names>V.</given-names></name><name name-style="western"><surname>Payrastre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vardon-Bounes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ribes</surname><given-names>A.</given-names></name></person-group><article-title>Platelet Versus Megakaryocyte: Who Is the Real Bandleader of Thromboinflammation in Sepsis?</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>1507</elocation-id><pub-id pub-id-type="doi">10.3390/cells11091507</pub-id><pub-id pub-id-type="pmid">35563812</pub-id><pub-id pub-id-type="pmcid">PMC9104300</pub-id></element-citation></ref><ref id="B36-ijms-23-14694"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Atri</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Miguel</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Pozner</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Ortiz Wilczynski</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Negrotto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carrera-Silva</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Schattner</surname><given-names>M.</given-names></name></person-group><article-title>Activation of toll-like receptors 2 and 4 on CD34(+) cells increases human megakaryo/thrombopoiesis induced by thrombopoietin</article-title><source>J. Thromb. Haemost.</source><year>2019</year><volume>17</volume><fpage>2196</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1111/jth.14605</pub-id><pub-id pub-id-type="pmid">31397069</pub-id></element-citation></ref><ref id="B37-ijms-23-14694"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fraughton</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.R.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Harris</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Supiano</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Grissom</surname><given-names>C.K.</given-names></name></person-group><article-title>Platelet-monocyte aggregate formation and mortality risk in older patients with severe sepsis and septic shock</article-title><source>J. Gerontol. Ser. A Biol. Sci. Med. Sci.</source><year>2015</year><volume>70</volume><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1093/gerona/glu082</pub-id><pub-id pub-id-type="pmid">24917177</pub-id><pub-id pub-id-type="pmcid">PMC4366600</pub-id></element-citation></ref><ref id="B38-ijms-23-14694"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkata</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>R.</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Afessa</surname><given-names>B.</given-names></name></person-group><article-title>Thrombocytopenia in adult patients with sepsis: Incidence, risk factors, and its association with clinical outcome</article-title><source>J. Intensive Care</source><year>2013</year><volume>1</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/2052-0492-1-9</pub-id><pub-id pub-id-type="pmid">25810916</pub-id><pub-id pub-id-type="pmcid">PMC4373028</pub-id></element-citation></ref><ref id="B39-ijms-23-14694"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaguchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Pradier</surname><given-names>O.</given-names></name></person-group><article-title>Platelet function in sepsis</article-title><source>J. Thromb. Haemost.</source><year>2004</year><volume>2</volume><fpage>2096</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.01009.x</pub-id><pub-id pub-id-type="pmid">15613012</pub-id></element-citation></ref><ref id="B40-ijms-23-14694"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hirosumi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sugasawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanaoka</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M.</given-names></name></person-group><article-title>Purification and initial characterization of a protein which facilitates assembly of nucleosome-like structure from mammalian cells</article-title><source>Eur. J. Biochem.</source><year>1984</year><volume>142</volume><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1984.tb08305.x</pub-id><pub-id pub-id-type="pmid">6468372</pub-id></element-citation></ref><ref id="B41-ijms-23-14694"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zlatanova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seebart</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tomschik</surname><given-names>M.</given-names></name></person-group><article-title>Nap1: Taking a closer look at a juggler protein of extraordinary skills</article-title><source>FASEB J.</source><year>2007</year><volume>21</volume><fpage>1294</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1096/fj.06-7199rev</pub-id><pub-id pub-id-type="pmid">17317729</pub-id></element-citation></ref><ref id="B42-ijms-23-14694"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Nucleosome Assembly Protein 1-Like 1 (Nap1l1) Regulates the Proliferation of Murine Induced Pluripotent Stem Cells</article-title><source>Cell Physiol. Biochem.</source><year>2016</year><volume>38</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1159/000438634</pub-id><pub-id pub-id-type="pmid">26824453</pub-id></element-citation></ref><ref id="B43-ijms-23-14694"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okuwaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>K.</given-names></name></person-group><article-title>Functional characterization of human nucleosome assembly protein 1-like proteins as histone chaperones</article-title><source>Genes Cells</source><year>2010</year><volume>15</volume><fpage>13</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2009.01361.x</pub-id><pub-id pub-id-type="pmid">20002496</pub-id></element-citation></ref><ref id="B44-ijms-23-14694"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yip</surname><given-names>M.C.J.</given-names></name><name name-style="western"><surname>Sedor</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>S.</given-names></name></person-group><article-title>Mechanism of client selection by the protein quality-control factor UBE2O</article-title><source>Nat. Struct. Mol. Biol.</source><year>2022</year><volume>29</volume><fpage>774</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/s41594-022-00807-6</pub-id><pub-id pub-id-type="pmid">35915257</pub-id><pub-id pub-id-type="pmcid">PMC9526450</pub-id></element-citation></ref><ref id="B45-ijms-23-14694"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>NAP1L1 promotes the growth of colon cancer by activating HDGF/DDX5</article-title><source>Acta Biochim. Biophys. Sin.</source><year>2022</year><pub-id pub-id-type="doi">10.3724/abbs.2022124</pub-id><pub-id pub-id-type="pmcid">PMC9828316</pub-id><pub-id pub-id-type="pmid">36148951</pub-id></element-citation></ref><ref id="B46-ijms-23-14694"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name></person-group><article-title>NAP1L1 Functions as a Novel Prognostic Biomarker Associated with Macrophages and Promotes Tumor Progression by Influencing the Wnt/beta-Catenin Pathway in Hepatocellular Carcinoma</article-title><source>Front. Genet.</source><year>2022</year><volume>13</volume><fpage>876253</fpage><pub-id pub-id-type="doi">10.3389/fgene.2022.876253</pub-id><pub-id pub-id-type="pmid">35664324</pub-id><pub-id pub-id-type="pmcid">PMC9161088</pub-id></element-citation></ref><ref id="B47-ijms-23-14694"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiaohua</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name></person-group><article-title>NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><elocation-id>339</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-022-09356-z</pub-id><pub-id pub-id-type="pmid">35351053</pub-id><pub-id pub-id-type="pmcid">PMC8962469</pub-id></element-citation></ref><ref id="B48-ijms-23-14694"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name></person-group><article-title>Trametes robiniophila represses angiogenesis and tumor growth of lung cancer via strengthening let-7d-5p and targeting NAP1L1</article-title><source>Bioengineered</source><year>2022</year><volume>13</volume><fpage>6698</fpage><lpage>6710</lpage><pub-id pub-id-type="doi">10.1080/21655979.2021.2012619</pub-id><pub-id pub-id-type="pmid">34898380</pub-id><pub-id pub-id-type="pmcid">PMC8973683</pub-id></element-citation></ref><ref id="B49-ijms-23-14694"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Oler</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Low</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Nix</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Yost</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name></person-group><article-title>Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>e101</fpage><lpage>e111</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-03-339705</pub-id><pub-id pub-id-type="pmid">21596849</pub-id><pub-id pub-id-type="pmcid">PMC3193274</pub-id></element-citation></ref><ref id="B50-ijms-23-14694"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Boer</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Houten</surname><given-names>S.M.</given-names></name></person-group><article-title>A mitochondrial expatriate: Nuclear pyruvate dehydrogenase</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>9</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.06.018</pub-id><pub-id pub-id-type="pmid">24995972</pub-id></element-citation></ref><ref id="B51-ijms-23-14694"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutendra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kinnaird</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dromparis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paulin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Haromy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Flaim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Michelakis</surname><given-names>E.D.</given-names></name></person-group><article-title>A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>84</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.04.046</pub-id><pub-id pub-id-type="pmid">24995980</pub-id></element-citation></ref><ref id="B52-ijms-23-14694"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colapietro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lleo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Generali</surname><given-names>E.</given-names></name></person-group><article-title>Antimitochondrial Antibodies: From Bench to Bedside</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2022</year><volume>63</volume><fpage>166</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1007/s12016-021-08904-y</pub-id><pub-id pub-id-type="pmid">34586589</pub-id><pub-id pub-id-type="pmcid">PMC8480115</pub-id></element-citation></ref><ref id="B53-ijms-23-14694"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Odin</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>M.E.</given-names></name></person-group><article-title>Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis</article-title><source>Hepatology</source><year>2004</year><volume>40</volume><fpage>1241</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1002/hep.20491</pub-id><pub-id pub-id-type="pmid">15558739</pub-id><pub-id pub-id-type="pmcid">PMC3140764</pub-id></element-citation></ref><ref id="B54-ijms-23-14694"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Luger</surname><given-names>K.</given-names></name></person-group><article-title>Structure and function of nucleosome assembly proteins</article-title><source>Biochem. Cell Biol.</source><year>2006</year><volume>84</volume><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1139/o06-088</pub-id><pub-id pub-id-type="pmid">16936827</pub-id></element-citation></ref><ref id="B55-ijms-23-14694"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Luger</surname><given-names>K.</given-names></name></person-group><article-title>The structure of nucleosome assembly protein 1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>1248</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508002103</pub-id><pub-id pub-id-type="pmid">16432217</pub-id><pub-id pub-id-type="pmcid">PMC1345705</pub-id></element-citation></ref><ref id="B56-ijms-23-14694"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hozumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ichimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iseki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yagisawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shinkawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Interaction of nucleosome assembly proteins abolishes nuclear localization of DGKzeta by attenuating its association with importins</article-title><source>Exp. Cell Res.</source><year>2011</year><volume>317</volume><fpage>2853</fpage><lpage>2863</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2011.09.014</pub-id><pub-id pub-id-type="pmid">21996351</pub-id></element-citation></ref><ref id="B57-ijms-23-14694"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strub</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Pfanner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Voos</surname><given-names>W.</given-names></name></person-group><article-title>The mitochondrial protein import motor</article-title><source>Biol. Chem.</source><year>2000</year><volume>381</volume><fpage>943</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1515/BC.2000.115</pub-id><pub-id pub-id-type="pmid">11076025</pub-id></element-citation></ref><ref id="B58-ijms-23-14694"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCall</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zabalawi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>D.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yoza</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Stacpoole</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Vachharajani</surname><given-names>V.</given-names></name></person-group><article-title>Sepsis, pyruvate, and mitochondria energy supply chain shortage</article-title><source>J. Leukoc. Biol.</source><year>2022</year><pub-id pub-id-type="doi">10.1002/JLB.3MR0322-692RR</pub-id><pub-id pub-id-type="pmcid">PMC9796618</pub-id><pub-id pub-id-type="pmid">35866365</pub-id></element-citation></ref><ref id="B59-ijms-23-14694"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Boyman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yadava</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lederer</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Pyruvate-Driven Oxidative Phosphorylation is Downregulated in Sepsis-Induced Cardiomyopathy: A Study of Mitochondrial Proteome</article-title><source>Shock</source><year>2022</year><volume>57</volume><fpage>553</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000001858</pub-id><pub-id pub-id-type="pmid">34506367</pub-id><pub-id pub-id-type="pmcid">PMC8904652</pub-id></element-citation></ref><ref id="B60-ijms-23-14694"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Portier</surname><given-names>I.</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Eustes</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>Human platelets display dysregulated sepsis-associated autophagy, induced by altered LC3 protein-protein interaction of the Vici-protein EPG5</article-title><source>Autophagy</source><year>2021</year><volume>18</volume><fpage>1534</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1080/15548627.2021.1990669</pub-id><pub-id pub-id-type="pmid">34689707</pub-id><pub-id pub-id-type="pmcid">PMC9298447</pub-id></element-citation></ref><ref id="B61-ijms-23-14694"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manne</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Bhatlekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Borst</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>Phospho-inositide-dependent kinase 1 regulates signal dependent translation in megakaryocytes and platelets</article-title><source>J. Thromb. Haemost.</source><year>2020</year><volume>18</volume><fpage>1183</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1111/jth.14748</pub-id><pub-id pub-id-type="pmid">31997536</pub-id><pub-id pub-id-type="pmcid">PMC7192796</pub-id></element-citation></ref><ref id="B62-ijms-23-14694"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montenont</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bhatlekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kosaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Manne</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>O.</given-names></name><name name-style="western"><surname>Parra-Izquierdo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tugolukova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>CRISPR-edited megakaryocytes for rapid screening of platelet gene functions</article-title><source>Blood Adv.</source><year>2021</year><volume>5</volume><fpage>2362</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020004112</pub-id><pub-id pub-id-type="pmid">33944898</pub-id><pub-id pub-id-type="pmcid">PMC8114553</pub-id></element-citation></ref><ref id="B63-ijms-23-14694"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pendaries</surname><given-names>C.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Spalton</surname><given-names>J.C.</given-names></name></person-group><article-title>Methods for genetic modification of megakaryocytes and platelets</article-title><source>Platelets</source><year>2007</year><volume>18</volume><fpage>393</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1080/09537100701288012</pub-id><pub-id pub-id-type="pmid">17763148</pub-id></element-citation></ref><ref id="B64-ijms-23-14694"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koupenova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Livada</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Morrell</surname><given-names>C.N.</given-names></name></person-group><article-title>Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity</article-title><source>Circ. Res.</source><year>2022</year><volume>130</volume><fpage>288</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.319821</pub-id><pub-id pub-id-type="pmid">35050690</pub-id><pub-id pub-id-type="pmcid">PMC8852355</pub-id></element-citation></ref><ref id="B65-ijms-23-14694"><label>65.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lindemann</surname><given-names>S.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>A.S.</given-names></name></person-group><article-title>Platelet Signal-Dependent Protein Synthesis</article-title><source>Platelet Function: Assessment, Diagnosis, and Treatment</source><person-group person-group-type="editor"><name name-style="western"><surname>Fitzgerald</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>M.</given-names></name></person-group><publisher-name>The Humana Press Inc.</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2005</year><fpage>151</fpage><lpage>176</lpage></element-citation></ref><ref id="B66-ijms-23-14694"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kahr</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Michetti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Weitz</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Blaylock</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Kraiss</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Greinacher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Anucleate platelets generate progeny</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>3801</fpage><lpage>3809</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-08-239558</pub-id><pub-id pub-id-type="pmid">20086251</pub-id><pub-id pub-id-type="pmcid">PMC2865870</pub-id></element-citation></ref><ref id="B67-ijms-23-14694"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rondina</surname><given-names>M.T.</given-names></name></person-group><article-title>Platelets and their Microparticles go hand in hand</article-title><source>Thromb. Res.</source><year>2018</year><volume>168</volume><fpage>164</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2018.07.018</pub-id><pub-id pub-id-type="pmid">30060877</pub-id></element-citation></ref><ref id="B68-ijms-23-14694"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Chaoji</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maiguel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Faridi</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Barth</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stoub</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krastins</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ogihara</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Proteomic and phospho-proteomic profile of human platelets in basal, resting state: Insights into integrin signaling</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e7627</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007627</pub-id><pub-id pub-id-type="pmid">19859549</pub-id><pub-id pub-id-type="pmcid">PMC2762604</pub-id></element-citation></ref><ref id="B69-ijms-23-14694"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bishop-Bailey</surname><given-names>D.</given-names></name></person-group><article-title>The platelet as a model system for the acute actions of nuclear receptors</article-title><source>Steroids</source><year>2010</year><volume>75</volume><fpage>570</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2009.09.005</pub-id><pub-id pub-id-type="pmid">19778546</pub-id></element-citation></ref><ref id="B70-ijms-23-14694"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hitzler</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Ameur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Provost</surname><given-names>P.</given-names></name></person-group><article-title>Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0133070</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0133070</pub-id><pub-id pub-id-type="pmid">26172280</pub-id><pub-id pub-id-type="pmcid">PMC4501785</pub-id></element-citation></ref><ref id="B71-ijms-23-14694"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Heald</surname><given-names>R.</given-names></name></person-group><article-title>Glutamylation of Nap1 modulates histone H1 dynamics and chromosome condensation in Xenopus</article-title><source>J. Cell Biol.</source><year>2015</year><volume>209</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1083/jcb.201412097</pub-id><pub-id pub-id-type="pmid">25897082</pub-id><pub-id pub-id-type="pmcid">PMC4411273</pub-id></element-citation></ref><ref id="B72-ijms-23-14694"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>H.U.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hogg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Branch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ishimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Siminovitch</surname><given-names>K.A.</given-names></name></person-group><article-title>Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation</article-title><source>Biochem. J.</source><year>1994</year><volume>297</volume><issue-part>Pt 2</issue-part><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1042/bj2970389</pub-id><pub-id pub-id-type="pmid">8297347</pub-id><pub-id pub-id-type="pmcid">PMC1137842</pub-id></element-citation></ref><ref id="B73-ijms-23-14694"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Alexeyev</surname><given-names>M.</given-names></name><name name-style="western"><surname>King</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yoder</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>T.</given-names></name></person-group><article-title>Regulatory role for nucleosome assembly protein-1 in the proliferative and vasculogenic phenotype of pulmonary endothelium</article-title><source>Am. J. Physiol. Lung. Cell Mol. Physiol.</source><year>2008</year><volume>294</volume><fpage>L431</fpage><lpage>L439</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00316.2007</pub-id><pub-id pub-id-type="pmid">17981956</pub-id></element-citation></ref><ref id="B74-ijms-23-14694"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regnard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Desbruyeres</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huet</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Beauvallet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pernollet</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Edde</surname><given-names>B.</given-names></name></person-group><article-title>Polyglutamylation of nucleosome assembly proteins</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>15969</fpage><lpage>15976</lpage><pub-id pub-id-type="doi">10.1074/jbc.M000045200</pub-id><pub-id pub-id-type="pmid">10747868</pub-id></element-citation></ref><ref id="B75-ijms-23-14694"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dijk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Strub</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lacroix</surname><given-names>B.</given-names></name><name name-style="western"><surname>van Dorsselaer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Edde</surname><given-names>B.</given-names></name><name name-style="western"><surname>Janke</surname><given-names>C.</given-names></name></person-group><article-title>Polyglutamylation is a post-translational modification with a broad range of substrates</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>3915</fpage><lpage>3922</lpage><pub-id pub-id-type="doi">10.1074/jbc.M705813200</pub-id><pub-id pub-id-type="pmid">18045879</pub-id></element-citation></ref><ref id="B76-ijms-23-14694"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cytosolic carboxypeptidase CCP6 is required for megakaryopoiesis by modulating Mad2 polyglutamylation</article-title><source>J. Exp. Med.</source><year>2014</year><volume>211</volume><fpage>2439</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1084/jem.20141123</pub-id><pub-id pub-id-type="pmid">25332286</pub-id><pub-id pub-id-type="pmcid">PMC4235637</pub-id></element-citation></ref><ref id="B77-ijms-23-14694"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ihara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanuma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kakizuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ikura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ikura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>T.</given-names></name></person-group><article-title>Nuclear pyruvate kinase M2 complex serves as a transcriptional coactivator of arylhydrocarbon receptor</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>636</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv967</pub-id><pub-id pub-id-type="pmid">26405201</pub-id><pub-id pub-id-type="pmcid">PMC4737187</pub-id></element-citation></ref><ref id="B78-ijms-23-14694"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chueh</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Cronk</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Venkitachalam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pabich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.L.</given-names></name></person-group><article-title>Nuclear localization of pyruvate dehydrogenase complex-E2 (PDC-E2), a mitochondrial enzyme, and its role in signal transducer and activator of transcription 5 (STAT5)-dependent gene transcription</article-title><source>Cell Signal.</source><year>2011</year><volume>23</volume><fpage>1170</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2011.03.004</pub-id><pub-id pub-id-type="pmid">21397011</pub-id><pub-id pub-id-type="pmcid">PMC3096605</pub-id></element-citation></ref><ref id="B79-ijms-23-14694"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thekkumkara</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wexler</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Pons</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.S.</given-names></name></person-group><article-title>Nucleotide sequence of a cDNA for the dihydrolipoamide acetyltransferase component of human pyruvate dehydrogenase complex</article-title><source>FEBS Lett.</source><year>1988</year><volume>240</volume><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(88)80337-5</pub-id><pub-id pub-id-type="pmid">3191998</pub-id></element-citation></ref><ref id="B80-ijms-23-14694"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kagaya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>K.</given-names></name></person-group><article-title>Molecular cloning, and characterization and expression of dihydrolipoamide acetyltransferase component of murine pyruvate dehydrogenase complex in bile duct cancer cells</article-title><source>J. Gastroenterol.</source><year>2002</year><volume>37</volume><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1007/s005350200065</pub-id><pub-id pub-id-type="pmid">12108679</pub-id></element-citation></ref><ref id="B81-ijms-23-14694"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stelzl</surname><given-names>U.</given-names></name><name name-style="western"><surname>Worm</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lalowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haenig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brembeck</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Goehler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stroedicke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zenkner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schoenherr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koeppen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A human protein-protein interaction network: A resource for annotating the proteome</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>957</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.08.029</pub-id><pub-id pub-id-type="pmid">16169070</pub-id></element-citation></ref><ref id="B82-ijms-23-14694"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arulkumaran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Deutschman</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Pinsky</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Zuckerbraun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schumacker</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kellum</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Workgroup</surname><given-names>A.X.</given-names></name></person-group><article-title>Mitochondrial Function in Sepsis</article-title><source>Shock</source><year>2016</year><volume>45</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000000463</pub-id><pub-id pub-id-type="pmid">26871665</pub-id><pub-id pub-id-type="pmcid">PMC4755359</pub-id></element-citation></ref><ref id="B83-ijms-23-14694"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayler</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Panagiotopoulos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elz</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>M.J.</given-names></name></person-group><article-title>Calcium-mediated damage during post-ischaemic reperfusion</article-title><source>J. Mol. Cell Cardiol.</source><year>1988</year><volume>20</volume><issue>(Suppl. 2)</issue><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/0022-2828(88)90331-8</pub-id><pub-id pub-id-type="pmid">3411616</pub-id></element-citation></ref><ref id="B84-ijms-23-14694"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name></person-group><article-title>The Pyruvate Dehydrogenase Complex Mitigates LPS-Induced Endothelial Barrier Dysfunction by Metabolic Regulation</article-title><source>Shock</source><year>2022</year><volume>57</volume><fpage>308</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000001931</pub-id><pub-id pub-id-type="pmid">35759309</pub-id></element-citation></ref><ref id="B85-ijms-23-14694"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>An</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>The Pyruvate Dehydrogenase Complex in Sepsis: Metabolic Regulation and Targeted Therapy</article-title><source>Front. Nutr.</source><year>2021</year><volume>8</volume><fpage>783164</fpage><pub-id pub-id-type="doi">10.3389/fnut.2021.783164</pub-id><pub-id pub-id-type="pmid">34970577</pub-id><pub-id pub-id-type="pmcid">PMC8712327</pub-id></element-citation></ref><ref id="B86-ijms-23-14694"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puskarich</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kline</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Shirey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hosler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>A.E.</given-names></name></person-group><article-title>Early alterations in platelet mitochondrial function are associated with survival and organ failure in patients with septic shock</article-title><source>J. Crit. Care</source><year>2016</year><volume>31</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2015.10.005</pub-id><pub-id pub-id-type="pmid">26511963</pub-id><pub-id pub-id-type="pmcid">PMC4690781</pub-id></element-citation></ref><ref id="B87-ijms-23-14694"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sjovall</surname><given-names>F.</given-names></name><name name-style="western"><surname>Morota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gnaiger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Elmer</surname><given-names>E.</given-names></name></person-group><article-title>Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis</article-title><source>Crit. Care</source><year>2010</year><volume>14</volume><fpage>R214</fpage><pub-id pub-id-type="doi">10.1186/cc9337</pub-id><pub-id pub-id-type="pmid">21106065</pub-id><pub-id pub-id-type="pmcid">PMC3219983</pub-id></element-citation></ref><ref id="B88-ijms-23-14694"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCann</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jennaro</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Stringer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Puskarich</surname><given-names>M.A.</given-names></name></person-group><article-title>A Multivariate Metabolomics Method for Estimating Platelet Mitochondrial Oxygen Consumption Rates in Patients with Sepsis</article-title><source>Metabolites</source><year>2020</year><volume>10</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.3390/metabo10040139</pub-id><pub-id pub-id-type="pmid">32252461</pub-id><pub-id pub-id-type="pmcid">PMC7240966</pub-id></element-citation></ref><ref id="B89-ijms-23-14694"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Doetsch</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>A.H.</given-names></name></person-group><article-title>Mechanisms Regulating Protein Localization</article-title><source>Traffic</source><year>2015</year><volume>16</volume><fpage>1039</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1111/tra.12310</pub-id><pub-id pub-id-type="pmid">26172624</pub-id></element-citation></ref><ref id="B90-ijms-23-14694"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munford</surname><given-names>R.S.</given-names></name></person-group><article-title>Severe sepsis and septic shock: The role of gram-negative bacteremia</article-title><source>Annu. Rev. Pathol.</source><year>2006</year><volume>1</volume><fpage>467</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100200</pub-id><pub-id pub-id-type="pmid">18039123</pub-id></element-citation></ref><ref id="B91-ijms-23-14694"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schrottmaier</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Salzmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rayes</surname><given-names>J.</given-names></name></person-group><article-title>Platelets in Sepsis: An Update on Experimental Models and Clinical Data</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1687</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01687</pub-id><pub-id pub-id-type="pmid">31379873</pub-id><pub-id pub-id-type="pmcid">PMC6650595</pub-id></element-citation></ref><ref id="B92-ijms-23-14694"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muronoi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tonai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Koinuma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shima</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nunomiya</surname><given-names>S.</given-names></name></person-group><article-title>Time course of immature platelet count and its relation to thrombocytopenia and mortality in patients with sepsis</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0192064</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0192064</pub-id><pub-id pub-id-type="pmid">29381746</pub-id><pub-id pub-id-type="pmcid">PMC5790259</pub-id></element-citation></ref><ref id="B93-ijms-23-14694"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cataldo</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ravid</surname><given-names>K.</given-names></name></person-group><article-title>Rat NAP1: cDNA cloning and upregulation by Mpl ligand</article-title><source>Gene</source><year>1999</year><volume>226</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(98)00563-0</pub-id><pub-id pub-id-type="pmid">9931510</pub-id></element-citation></ref><ref id="B94-ijms-23-14694"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dellinger</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Carlet</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bion</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Jaeschke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reinhart</surname><given-names>K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Brun-Buisson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beale</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008</article-title><source>Crit. Care Med.</source><year>2008</year><volume>36</volume><fpage>296</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000298158.12101.41</pub-id><pub-id pub-id-type="pmid">18158437</pub-id></element-citation></ref><ref id="B95-ijms-23-14694"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahr</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Hinckley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schwertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Pluthero</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fabbro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome</article-title><source>Nat. Genet.</source><year>2011</year><volume>43</volume><fpage>738</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1038/ng.884</pub-id><pub-id pub-id-type="pmid">21765413</pub-id><pub-id pub-id-type="pmcid">PMC6050511</pub-id></element-citation></ref><ref id="B96-ijms-23-14694"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>London</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Sauvaget</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stockton</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Wythe</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>W.</given-names></name><name name-style="western"><surname>Larrieu-Lahargue</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mukouyama</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability</article-title><source>Nat. Med.</source><year>2008</year><volume>14</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1038/nm1742</pub-id><pub-id pub-id-type="pmid">18345009</pub-id><pub-id pub-id-type="pmcid">PMC2875252</pub-id></element-citation></ref><ref id="B97-ijms-23-14694"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eng</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>J.R.</given-names></name></person-group><article-title>An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database</article-title><source>J. Am. Soc. Mass Spectrom.</source><year>1994</year><volume>5</volume><fpage>976</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/1044-0305(94)80016-2</pub-id><pub-id pub-id-type="pmid">24226387</pub-id></element-citation></ref><ref id="B98-ijms-23-14694"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nesvizhskii</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Kolker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aebersold</surname><given-names>R.</given-names></name></person-group><article-title>Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search</article-title><source>Anal. Chem.</source><year>2002</year><volume>74</volume><fpage>5383</fpage><lpage>5392</lpage><pub-id pub-id-type="doi">10.1021/ac025747h</pub-id><pub-id pub-id-type="pmid">12403597</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-23-14694-f001" orientation="portrait"><label>Figure 1</label><caption><p><bold>MKs and human PLTs express mRNA for NAP1L1.</bold> RNA-seq snapshots taken from the Integrated Genome Browser of the <italic toggle="yes">NAP1L1</italic> transcript in CD34+-derived MKs (<bold>A</bold>) and human PLTs (<bold>B</bold>) (representative for n = 3). The height on the <italic toggle="yes">y</italic>-axis represents the relative accumulated number of reads spanning a particular sequence. The average of the read depths across all genomic coordinates within a transcript correlate to abundance of RNA expression. <italic toggle="yes">NAP1L1</italic> transcript regions are represented below the plots by thick (exon) and thin (intron) lines. (<bold>C</bold>) MKs at culture days 3, 5, 7, 10, and 14 were examined for <italic toggle="yes">NAP1L1</italic> expression by PCR. NT represents the reverse transcription (RT) reaction using no template, NE represents the RT reaction using no enzyme. Both controls were performed to control for contaminating nuclear DNA. <bold>Bottom</bold>, <italic toggle="yes">B2M</italic> as a loading control. This figure is representative of 5 independent experiments. (<bold>D</bold>) RNA from freshly isolated PLTs at baseline was isolated and <italic toggle="yes">NAP1L1</italic> mRNA expression was evaluated by PCR. This figure is representative of 3 independent experiments. The -PCR lane shows the negative control for the PCR reaction, lanes labeled with M indicate the marker lane.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-23-14694-g001.jpg"/></fig><fig position="float" id="ijms-23-14694-f002" orientation="portrait"><label>Figure 2</label><caption><p><bold>MKs and human PLTs express alternative <italic toggle="yes">NAP1L1</italic> transcript variants.</bold> (<bold>A</bold>) Schematic representation of the organization of exons in NAP1L1 transcript variant 1 (<bold>top</bold>), and transcript variant 5 (<bold>bottom</bold>) missing exons 3 and 4. Primer binding sites for transcript variant 1 detection (green, as used in <xref rid="ijms-23-14694-f001" ref-type="fig">Figure 1</xref>) and transcript variant 5 (orange), and the expected PCR products (dark red) are indicated. (<bold>B</bold>) MKs at culture days 3, 5, 7, 10, and 14 were examined for <italic toggle="yes">NAP1L1</italic> expression by PCR. NT represents the reverse transcription (RT) reaction using no template, NE represents the RT reaction using no enzyme. Both controls were performed to control for contaminating nuclear DNA. <bold>Bottom</bold>, <italic toggle="yes">B2M</italic> as a loading control. This figure is representative of 5 independent experiments. (<bold>C</bold>) RNA from freshly isolated PLTs at baseline (BL) and after culture overnight (ON) was isolated and <italic toggle="yes">NAP1L1</italic> mRNA expression was evaluated by PCR. This figure is representative of 10 independent experiments. The -PCR lane shows the negative control for the PCR reaction, lanes labeled with M indicate the marker lane. Relevant PCR products are indicated by yellow arrows.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-23-14694-g002.jpg"/></fig><fig position="float" id="ijms-23-14694-f003" orientation="portrait"><label>Figure 3</label><caption><p><bold>MKs and human PLTs express NAP1L1 protein.</bold> (<bold>A</bold>) CD34<sup>+</sup>-derived MKs were placed on immobilized fibrinogen to induce proplatelet formation, fixed, and then incubated with an antibody against NAP1L1 (yellow, top right panel) or an IgG control, followed by co-staining for b-tubulin (magenta) and nuclei (40,6-diamidino-2-phenylindole, DAPI, blue), as shown in the bottom panels. Scale bars = 20 &#181;m. This figure is representative of n = 7 independent experiments. (<bold>B</bold>) NAP1L1 protein expression (green) in human PLTs. PLTs incubated with an IgG control antibody are shown (left, IgG). The bottom panels show the corresponding transmission images overlayed with the co-staining with WGA (red). Scale bars = 10 &#181;m. This figure is representative of n = 6 independent experiments. (<bold>C</bold>) Immunoblot analysis of MK lysates (day 13 of culture) using the anti-NAP1L1 antibody. The cells were lysed, and proteins separated by SDS-PAGE electrophoresis. NAP1L1 isoforms are highlighted by a red box. (<bold>D</bold>) Immunoblot analysis of PLT lysates using the anti-NAP1L1 antibody. The cells were lysed, and proteins separated by SDS-PAGE electrophoresis; however, the samples were split and processed in parallel in the absence (<bold>left</bold>) or presence (<bold>right</bold>) of an NAP1L1-quenching peptide. The presence of the blocking peptide prevents the detection of NAP1L1 with the anti-NAP1L1 antibody, demonstrating specificity for the three main NAP1L1 protein isoforms. Lanes labeled with M indicate the marker lane. (<bold>C</bold>,<bold>D</bold>), representative of 3 and 8 independent experiments, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-23-14694-g003.jpg"/></fig><fig position="float" id="ijms-23-14694-f004" orientation="portrait"><label>Figure 4</label><caption><p><bold>NAP1L1 directly interacts with PDC-E2.</bold> (<bold>A</bold>) Sodium dodecyl sulfate (SDS) gel were stained for total protein using standard MS-compatible silver staining. The left lane shows proteins isolated after co-immunoprecipitation (co-IP) using an anti-NAP1L1 antibody. The middle lane shows proteins isolated after co-IP with non-immunogenic, control IgG. The right lane shows proteins isolated after the use of protein-G beads only. Red box marks selected protein band subsequently used in MS analysis. This figure is representative of n = 5 independent experiments. (<bold>B</bold>) Bar graph showing the total spectrum count per protein. Black bars show counts for MS performed after control IgG experiment; non-filled bars demonstrated spectrum counts for proteins identified after co-IP using anti-NAP1L1. Total spectrum counts for PDC-E2 are indicated by red asterisk. (<bold>C</bold>) Bar graph showing the normalized spectrum count (normalized to all total spectrum counts) for PDC-E2. Black bar represents counts for MS performed after control IgG experiment; non-filled bar show spectrum counts for PDC-E2 identified after co-IP using anti-NAP1L1. This figure is representative of n = 3 independent experiments. Analyzed using <italic toggle="yes">t</italic>-test, <italic toggle="yes">p</italic> = 0.0271. (<bold>D</bold>) A corresponding sodium dodecyl sulfate (SDS) gel was analyzed using immunoblotting technique. Co-IP proteins were probed using an anti-PDC-E2 antibody. The left lane shows proteins isolated after co-immunoprecipitation (co-IP) using an anti-NAP1L1 antibody. The middle lane shows proteins isolated after co-IP with non-immunogenic, control IgG. The right lane shows proteins isolated after the use of protein-G beads only. Red box and yellow arrow mark PDC-E2 protein detected as being co-IP&#8217;ed using the anti-NAP1L1 antibody, indicating protein&#8211;protein interaction. This figure is representative of n = 3 independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-23-14694-g004.jpg"/></fig><fig position="float" id="ijms-23-14694-f005" orientation="portrait"><label>Figure 5</label><caption><p><bold>NAP1L1 shows dynamic protein expression changes when PLTs are exposed to septic conditions.</bold> PLTs were isolated from healthy individuals or septic patients within 48 h of ICU admission. (<bold>A</bold>) Total RNA was isolated and next generation RNA-sequencing (RNA-seq) was performed (n = 9, and 17, for septic and healthy, respectively). Data show the RPKM expression for NAP1L1 for healthy (grey), and septic (non-filled) samples. Analyzed using <italic toggle="yes">t</italic>-test, <italic toggle="yes">p</italic> = 0.0001. (<bold>B</bold>) PLTs were fixed in suspension immediately after isolation. Immunofluorescence staining with an anti-NAP1L1 (green) antibody demonstrates robust expression of NAP1L1 protein in PLTs from septic patients and healthy PLTs (scale bars: 10 &#181;m). Cells were co-stained using WGA (red). This figure is representative of n = 6 independent experiments. (<bold>C</bold>) Micrographs were analyzed using CellProfiler. The bar graph displays the mean intensity over all stained cells for NAP1L1, normalized to IgG. Analyzed using <italic toggle="yes">t</italic>-test, <italic toggle="yes">p</italic> = 0.0505. (<bold>D</bold>) PLTs from healthy individuals and septic patients were isolated. NAP1L1 protein expression levels were detected by Western blot. Positions of NAP1L1 isoforms are marked. Corresponding tubulin is shown at the bottom and was used for normalization of data presented in bar graph shown in (<bold>E</bold>) below. This figure is representative of n = 6 independent experiments. Analyzed using Mann&#8211;Whitney test, <italic toggle="yes">p</italic> = 0.0368.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-23-14694-g005.jpg"/></fig><fig position="float" id="ijms-23-14694-f006" orientation="portrait"><label>Figure 6</label><caption><p><bold>PDC-E2 protein levels and pyruvate dehydrogenase complex activity is increased in PLTs during sepsis.</bold> PLTs from healthy individuals and septic patients were isolated. (<bold>A</bold>) PDC-E2 protein expression levels were detected by Western blot. Position of PDC-E2 is marked. Corresponding actin (ACTB) is shown at the bottom and was used for the normalization of data presented in the bar graph shown in (<bold>B</bold>) below. This figure is representative of n = 3 independent experiments. Analyzed using <italic toggle="yes">t</italic>-test, <italic toggle="yes">p</italic> = 0.0360. (<bold>C</bold>) Pyruvate dehydrogenase complex activity assay was performed on PLTs isolated from septic (n = 13) and healthy (n = 11) individuals. Bar graph depicts mean optical signal &#177; SEM. Analyzed using <italic toggle="yes">t</italic>-test, <italic toggle="yes">p</italic> = 0.0278.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-23-14694-g006.jpg"/></fig><fig position="float" id="ijms-23-14694-f007" orientation="portrait"><label>Figure 7</label><caption><p><bold>NAP1L1 overexpression in MKs results in decreased (PPF).</bold> (<bold>A</bold>) Schematic of protocol for NAP1L1 overexpression in MKs. Functional elements of the NAP1L1 expression plasmid are demonstrated. (<bold>B</bold>) Immunoblot analysis of MK lysates (day 13 of culture) using the anti-NAP1L1 antibody. Cells were lysed and proteins separated by SDS-PAGE electrophoresis. Samples undergoing transfection with the in vitro transcribed NAP1L1 mRNA are labeled with NAP1L1; LPS-treatment groups are indicated. The bar graph shows a fold increase over non-treated cells (NoTx). This figure is representative of n = 2/3 independent experiments, as indicated by single data points. Analyzed using one way ANOVA, followed by Tukey&#8217;s multiple comparison, <italic toggle="yes">p</italic> = 0.0310. (<bold>C</bold>) Plot of percentages of day 13 MKs with PPs after being not treated (noTx), treated with LPS, or undergoing NAP1L1 transfection (NAP1L1). Asterisks indicate a significant decrease in PPF when compared to noTx and vehicle. This figure is representative of n = 4 independent experiments. Analyzed using one way ANOVA, followed by Tukey&#8217;s multiple comparison, noTx vs. vehicle, <italic toggle="yes">p</italic> = 0.8687, noTx vs. NAP1L1, <italic toggle="yes">p</italic> = 0.0064, noTx vs. vehicle LPS, <italic toggle="yes">p</italic> = 0.0009, noTx vs. NAP1L1 LPS, <italic toggle="yes">p</italic> =&lt; 0.0001, vehicle vs. NAP1L1, <italic toggle="yes">p</italic> = 0.0406, vehicle vs. vehicle LPS, <italic toggle="yes">p</italic> = 0.0058, vehicle vs. NAP1L1 LPS, <italic toggle="yes">p</italic> = 0.0002, NAP1L1 vs. vehicle LPS, <italic toggle="yes">p</italic> = 0.8467, NAP1L1 vs. NAP1L1 LPS, <italic toggle="yes">p</italic> = 0.0992, vehicle LPS vs. NAP1L1 LPS, <italic toggle="yes">p</italic> = 0.4623. (<bold>D</bold>) Representative brightfield images of MKs with PPs (yellow arrows) after <italic toggle="yes">NAP1L1</italic> overexpression, with or without LPS treatment. Scale bar: 50 &#181;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-23-14694-g007.jpg"/></fig></floats-group></article></pmc-articleset>